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                                                 INTRODUCTION
AN APPROACH TO THE PATIENT WITH NON OBSTRUCTIVE CORONARY ARTERY 
DISEASE 
Patients with Non Obstructive Coronary Artery Disease (NOCAD) utilize a significant part of 
our health care resources. Their diagnosis and treatment can often be difficult and time consuming.A 
simple classification system and stepwise diagnostic approach may help to reduce unnecessary testing. 
Also, utilization of a chest pain clinic may be beneficial for these patients.
Chest pain results in over 5 million visits to emergency departments, 2 million admissions, and 
multiple out patient consultations every year all over the world.A large number of these patients will 
eventually  undergo  coronary  angiography  and  depending  on  the  population  studied,  a  significant 
number  (20% to  30%)  will  have  normal-  appearing  coronary  arteries.Indeed,  10% to  15% of  all 
patients undergoing angiography in the catheterization laboratory have normal coronary arteries.(1)
The treatment and diagnosis of chest pain in patients with NOCAD continues to represent a 
major challenge to contemporary cardiology. When evaluating these patients, a revisit of the history 
and physical examination helps to narrow the extensive list of pathologic conditions in the differential 
diagnosis and focus further investigation. It is important to develop a logical, step-wise approach so as 
to limit unnecessary testing, expense, and patient discomfort.(1)
The evaluation of patients with chest pain and NOCAD should allow classification of  patients 
into 1 of 3 main groups. 
The  first  group  includes  patients  with  chest  pain  and  a  flow-limiting  coronary  lesion 
undetectable on routine angiography studies  but may be detected after physiologic evaluation.
The second group includes patients without significant atherosclerotic epicardial disease, but 
with evidence of epicardial flow or microvascular reactivity abnormalities that may lead to myocardial 
ischemia.
The  third  group  consists  of  patients  without  evidence  of  epicardial  or  microvascular 
abnormalities  after  extensive  coronary  and  physiologic  assessment.  This  group  will  need  further 
evaluation and assessment for a noncoronary or noncardiac etiology. 
ETIOLOGY OF CHEST PAIN
I. Coronary causes
A. Epicardial coronary etiology
1. Obstructive epicardial disease
2. Epicardial spasm
3. Epicardial bridging
4. Coronary dissection
5. Epicardial endothelial dysfunction and Slow Flow
B. Microvascular etiology
1. Microvascular endothelial dysfunction
2. Microvascular abnormalities secondary to valvular heart disease
3. Microvascular abnormalities secondary to  infiltrative disease
4. Microvascular abnormalities secondary to  hypertension
5. Microvascular abnormalities secondary to Cardiomyopathy
II. Noncoronary causes
A. Cardiac
1. Pericarditis
2. Myocarditis
B. Gastrointestinal
1. Biliary colic
2. GERD (gastroesophageal reflux disease)
3. PUD (peptic ulcer disease)
4. Pancreatitis
5. Esophageal dysmotility
C. Pulmonary
1. Spontaneous pneumothorax
2. Pulmonary embolus
3. Pneumonia
4. Pleuritis
D. Musculoskeletal
1. Costochondritis/Tietze syndrome
2. Myalgia
E. Vascular
1. Aortic dissection
2. Vasculitis
F. Endocrine disease
G. Drug-induced (Cocaine)
H. Enhanced pain perception/psychogenic
Epicardial Atherosclerotic Cause for Ischemia
It should be emphasized that physiologically significant coronary stenosis may not be readily 
apparent on angiography. A review of the angiogram and/or further assessment with fractional flow 
reserve(FFR) or intravascular ultrasound(IVUS) may be necessary to ensure there is  no significant 
epicardial coronary lesion.
Epicardial or Microvascular Cause for Ischemia
Once a flow-limiting lesion has been ruled out as a contributing factor for chest pain, other 
coronary abnormalities must be considered, including epicardial spasm, myocardial bridging, coronary 
dissection,epicardial  slow  flow  or  abnormalities  in  the  microvasculature.Myocardial  bridging  and 
dissection  should  be  readily  apparent  on  the  angiogram;  however,  epicardial  vasoconstriction  and 
abnormalities of the microvasculature will require further investigative and provocative procedures.
Epicardial Coronary Spasm
Epicardial coronary spasm was first described by Prinzmetal in 1959 and although relatively 
rare,should be considered in all patients with chest pain and NOCAD.It affects approximately 4 out of 
100,000 people (approximately 2% of patients complaining of angina).The epicardial coronary arteries 
can exhibit significant vasoactivity and patients with or without coronary atherosclerosis may have 
spontaneous increases in coronary vasomotor tone, resulting in myocardial ischemia.
 Patients often complain of nocturnal or early morning chest pain that typically occurs at rest and 
less so with exertion. In fact, they often maintain good exercise tolerance. 
This  atypical  presentation  of  epicardial  spasm  may  lead  to  chest  pain  symptoms  being 
erroneously dismissed as organic. Certain triggers can exacerbate coronary spasm, such as exposure to 
cold, emotional stress, alcohol, vasoconstricting medications, cocaine, or tobacco, and these should be 
avoided.  Furthermore,  coronary  vasospasm can  lead  to  cardiac  arrhythmias,  including  ventricular 
tachycardia/fibrillation,heart block, acute infarction, or sudden death.
The clinical history aids in the diagnosis of coronary vasospasm and noninvasive modalities 
such  as  ambulatory  Holter  monitoring,  documenting  ST-segment  elevation,  or  provocative 
echocardiography have been used in diagnosing vasospasm.If noninvasive testing is equivocal, then 
provocative testing with methylergonovine often demonstrates the presence of coronary spasm in these 
patients.Although normal vasoconstriction can result in as much as a 20% change in lumen diameter, 
coronary spasm is considered to be present when a reduction in lumen caliber 50% occurs during a 
provocative test and reversal is achieved with intracoronary nitroglycerin.
Treatment typically consists of medical therapy with calcium channel blockers and/or nitrates. 
Blockers should be used with caution as patients may experience a worsening of their symptoms due to 
unopposed alpha stimulation.The long-term prognosis of patients with variant angina is generally good 
if the patient is treated and avoids certain provocative stimuli.(1)
Microvascular Abnormalities
Patients with chest pain and/or evidence of myocardial ischemia and NOCAD and no other 
obvious  epicardial  etiology  should  undergo  evaluation  for  abnormalities  in  the  coronary 
microcirculation.With an increase in myocardial oxygen demand,there is an increase in coronary blood 
flow.The ability to increase coronary blood flow in response to vasoactive stimuli is termed coronary 
flow reserve  (CFR). CFR is determined by the ratio of maximal coronary blood flow to the resting 
coronary blood  flow.The major  epicardial  coronary arteries  only contribute about  5% to  the  total 
coronary vascular resistance.
The majority of coronary vascular resistance originates in the coronary arterioles, typically less 
than 300µm. Changes in the microcirculation may result in dramatic alterations in coronary blood flow 
and CFR, which may provoke ischemia. Cannon and Epstein proposed the term microvascular angina 
in 1985 for the symptoms of angina pectoris and a positive stress test in the setting of no significant 
epicardial stenosis.In the presence of normal epicardial arteries and normal microvasculature, the CFR 
is normal. However, severe flow-limiting epicardial stenosis or microvascular pathologic states of the 
coronary arterioles results in the diminution of CFR. Several pathologic entities are known to affect the 
coronary  microcirculation.  All  can  lead  to  some  abnormality  in  coronary  blood  flow  through 
endothelial dependent or independent mechanisms. 
Therefore,  patients  with chest  pain  and NOCAD should undergo assessment  of  endothelial 
dependent and independent abnormalities of the microcirculation,especially in the setting of disease 
states known to affect the microcirculation. 
Endothelial Dysfunction
 The endothelium plays a pivotal role in coronary homeostasis. It regulates vascular tone and 
coronary blood flow by releasing endothelial derived vasodilating factors such as nitric oxide (NO) and 
endothelial  derived  vasoconstrictors  such  as  endothelin.  It  also  plays  a  role  in  many physiologic 
processes such as inflammation,thrombosis, and platelet activation. 
Acetylcholine  (ACh)  stimulates  the  release  of NO  from  normal  endothelium,  which  then 
activates guanylate cyclase leading to an increased production of cyclic guanosine monophosphate and 
a reduction in intracellular calcium. It is apparent that NO is a key factor in vascular physiology and its 
bioavailability is vital in the maintenance of endothelial health. The degradation of NO is enhanced by 
reactive  oxidant  species  such  as  superoxide  anion  and  oxidized  low-density  lipoprotein  (LDL) 
cholesterol and this reduction in the bioavailability of NO can lead to abnormal coronary physiology.
Both invasive (with intracoronary ACh) and noninvasive (reactive hyperemia using brachial 
artery ultrasound) assessments of endothelial  function have been reported.In coronary arteries with 
normal  endothelium,  the  response  to  intracoronary  ACh  is  epicardial  and  microvascular  dilation 
resulting in an increase in coronary blood flow. However, when the endothelial lining is disrupted, 
intracoronary ACh induces vasoconstriction and a decrease in coronary blood flow. This endothelial-
dependent  response  to  ACh  may  serve  as  a  marker  for  the  bioavailability  of  NO.  Moreover,the 
abnormal coronary constriction response to ACh suggests a lack of NO bioavailability and denotes 
endothelial dysfunction.
The fact that the epicardial arteries may be angiographically free of disease does not preclude 
endothelial dysfunction; atherosclerosis may not be evident secondary to remodeling, diffuse disease, 
or may in fact be absent, as endothelial dysfunction is considered an early stage of atherosclerosis.
Moreover,  several  studies  have demonstrated that  endothelial  dysfunction is  not  just  a  risk 
factor and marker for developing atherosclerosis, but that inducible ischemia has been demonstrated in 
patients with nonobstructive coronary arteries and abnormal endothelial testing.Abnormal endothelial 
function serves as a prognostic indicator to future cardiac events. Treatment for endothelial dysfunction 
can  be  challenging  and should  always  include  risk  factor  modification  with  diet,exercise,  tobacco 
cessation, blood pressure control, glucose control, and lipid management.
Several studies have demonstrated abnormal coronary flow reserve in hypercholesterolemic or 
diabetic  patients  with  NOCAD.Statins  may have  a  significant  benefit  in  patients  with  endothelial 
dysfunction by improving lipid profiles and possibly through other mechanisms such as reduction of 
inflammation.(1)
C-reactive protein is a marker of systemic inflammation that has been shown to correlate with 
future cardiac events.It has also been suggested that elevated C-reactive protein is associated with the 
development of endothelial dysfunction.Blunted endothelial function has been demonstrated in patients 
with elevated C-reactive protein. 
Nonepicardial, Nonmicrovascular causes for Chest Pain
This group is the largest and most diverse of the three groups. It includes all other disease states 
not related to epicardial or microvascular disease.It is important to realize that these patients may still 
have  a  cardiac etiology for  their  pain,  such  as  pericarditis.They should all  be kept  in  mind when 
evaluating  the  etiology of  chest  pain  in  a  patient  with  NOCAD.  Moreover,  if  the  epicardial  and 
microvascular assessments are normal,  than consultation with other specialists  is important to help 
define the etiology of the chest pain.
Pericarditis
Pericardial and/or myocardial inflammation can mimic ischemic chest pain. Typically, the pain 
is described as sharp, retrosternal, and is aggravated by lying flat and improved by sitting up. The 
physical exam may reveal a pericardial friction rub or pericardial knock. The electrocardiogram usually 
demonstrates  diffuse  ST-segment  elevation.  However,  the  upward  concavity  of  the  ST  segment, 
absence  of  Q-waves  and  T-wave  inversions,  help  to  distinguish  pericarditis  from  acute  coronary 
syndromes. Pericarditis often responds well to nonsteroidal anti-inflammatory agents.
Vascular
Thoracic  aortic  dissection is  the most  common catastrophe of the aorta,  2 to  3 times more 
common than rupture of the abdominal aorta. When left untreated, about 35% of patients die within the 
first 24 hours, and  50% die within 48 hours. The pathologic features of aortic dissection consist of a 
tear in the intimal layer,  followed by formation and propagation of a subintimal hematoma. If the 
pericardial space is involved in the dissection, cardiac tamponade may result.
Chest pain is the most common presenting complaint in patients. The pain usually is described 
as ripping or tearing; however, this description is not universal, and some patients present with only 
mild pain. Patients may present with ischemic pain and electrocardiographic changes, if the coronary 
arteries are involved with the dissection. 
Smoking  and  hypertension  are  the  most  common  risk  factors  associated  with 
dissection.Although aortic dissection or penetrating aortic ulcers are unlikely to cause intermittent pain 
over several weeks, they should be considered in all patients complaining of acute, sudden, and severe 
chest  pain  that  is  maximal  at  onset.  Diagnosis  is  best  obtained  with  computed  tomography  or 
transesophageal echocardiography.
Gastrointestinal
Sir William Osler first  described the esophagus as a source of episodic chest  pain in 1892. 
Esophageal  abnormalities  represent  a  significant  percentage  of  patients  with noncardiac chest  pain 
(15% to  60%)  and  although  gastroesophageal  reflux  disease  and  esophageal  spasm are  the  most 
common causes for chest pain originating from the gastrointestinal  tract, one should also consider 
biliary colic, cholecystitis, and peptic ulcer disease.
It  is  not  inconceivable  that  esophageal  abnormalities  produce  similar  symptoms  as  cardiac 
ischemia because the distal esophagus and the heart have a common afferent nerve supply. History is 
often not helpful in discerning cardiac from esophageal chest pain because both can induce pressure or 
burning chest discomfort, which is exertional in nature.
Response to nitroglycerin is not a helpful clue either; nitroglycerin can relieve the discomfort 
produced by esophageal spasm by relaxing smooth muscle or via placebo effect. Also, patients with 
cardiac  and  esophageal  pain  often  have  similar  risk  factors,  namely,  tobacco  use  and  obesity. 
Endoscopy, manometry, and 24-hour pH monitoring have all been advocated in the work up of patients 
with chest pain and NOCAD. 
However  a  short  course  of  proton  pump  inhibition  is  more  sensitive  and  specific  for 
determining the cause of chest pain than endoscopy, manometry, or 24-hour pH monitoring. It may be 
reasonable  to  consider  acid  suppression  therapy  in  patients  prior  to  an  extensive  gastrointestinal 
workup. If the cardiac work-up is unremarkable, all patients with chest pain and NOCAD should be 
carefully screened for the occurrence of esophageal disorders. Referral to a gastroenterologist may be 
prudent.
Pulmonary
Several pathologies in the pulmonary system may lead to chest pain and should be considered 
in patients with chest pain and NOCAD. Important ones to rule out are pneumonia, pneumothorax, and 
pulmonary  embolism.The  first  2  should  be  readily  apparent  with  history,  physical  exam,  and 
radiographs;  however,  Pulmonary Embolism  frequently goes  undiagnosed and leads  to significant 
morbidity and mortality. It is estimated that pulmonary embolism leads to 50,000 to 200,000 deaths 
annually in the United States. The most common symptoms reported in pulmonary embolism include 
dyspnea, chest pain, and cough. 
Patients  often  develop  tachypnea,  rales,  and/or  tachycardia.  However,  chronic  pulmonary 
embolism  can  lead  to  less  dramatic  symptoms  and  patients  may  present  with  pulmonary 
hypertension.Diagnosis  is  best  obtained  with  computed  tomography  or  pulmonary  angiography. 
Therapy consists of anticoagulation.
Musculoskeletal
Tietze  syndrome  is  characterized  by  benign,  localized,  painful,  swelling  of  an  upper 
costochondral  area,  without  any  evidence  of  overlying  disease.  The  cause  is  unknown  and  the 
syndrome  usually  occurs  in  the  second  through  fourth  decades  of  life.  Tietze  syndrome  likely 
represents a small segment of the chest pain population. 
Epstein found that only 10% of patients seen for chest pain had a costochondral syndrome. 
Although it can be debilitating and associated with significant pain, it  is typically self-limiting and 
patients often obtain relief with nonsteroidal anti-inflammatory drugs.(1)
Enhanced Pain Perception/Psychogenic Pain
Psychological factors have been suspected as a cause of non cardiac chest pain for more than a 
century.It is found that 1 in 4 patients consulting an ambulatory emergency department for chest pain 
suffer from panic disorder. 
Enhanced  pain  perception  has  also  been  demonstrated  in  patients  with  chest  pain  and 
NOCAD.Intracardiac  catheter  manipulation  produced  typical  chest  pain  in  34  of  36  patients  with 
NOCAD, in the absence of any changes in Coronary Blood Flow  and that the same stimulus caused 
chest pain in only a small proportion of patients with coronary artery disease. A lower threshold for 
pain  perception  could  explain  the  occurrence  of  chest  pain  in  these  patients  without  involving  an 
ischemic mechanism.
Treatment and diagnosis of chest pain secondary to enhanced pain perception or psychiatric 
abnormalities can be difficult and many patients may not accept this explanation. Most patients benefit 
from counseling, which helps in reducing further health care utilization. Medical therapy often consists
of tricyclic antidepressants such as imipramine or benzodiazepines. Nonpharmacologic therapies may 
include  biotherapy  or  spinal  cord  stimulators. Spinal  cord  stimulation  has  been  shown  to  reduce 
symptoms and increase exercise capacity in patients with chest pain and NOCAD.
More recently in patients with chest pain and normal coronary arteries and it was found that 
elevated C-Reactive Protein  levels  correlated with symptoms and electrocardiographic markers  of 
myocardial ischemia. A number of studies have demonstrated that C-Reactive Protein levels can be 
lowered with statin therapy.It is plausible that statins may improve endothelial function by reducing or 
preventing inflammation.
Other therapies, such as angiotensin converting enzyme inhibition and anti oxidants have also 
shown some benefit in endothelial dysfunction. We have shown that oral L-arginine (a precursor to 
NO) improves endothelial function and  symptoms at 6 months.It is important to assess secondary 
conditions associated with chest pain and abnormal CFR, such as, hypertensive heart disease, valve 
disease, cardiomyopathy.
DIAGNOSIS
When  evaluating  patients  with  chest  pain,  the  role  of  the  cardiologist  is  to  determine  if 
symptoms are related to a cardiac etiology. It is important to realize that patients with NOCAD may 
need  further  testing  after  angiography  and  echocardiography.The  assessment  of  both  endothelial-
dependent and -independent epicardial  and microvascular abnormalities can often lead to a cardiac 
diagnosis that may have otherwise been missed. This in turn allows appropriate treatment options to be 
initiated and better outcomes for patients. 
Angiographic assessment of epicardial coronary artery blood flow has played a pivotal role in 
our understanding of the “time-dependent open artery hypothesis” and in the evaluation of reperfusion 
strategies over the past 2 decades.But it has become increasingly apparent,that clinical outcomes are 
not only associated with angiographic flow in the epicardial artery, but also with angiographic flow in 
the  myocardium.To  this  end,  the  goal  of  reperfusion  therapies  has  shifted  to  include  reperfusion 
downstream at the level of capillary bed, and it might be more appropriate that the hypothesis now be 
termed “the time dependent open artery and open microvascular hypothesis.”(52)
Although the TIMI (Thrombolysis In Myocardial Infarction) flow grade classification scheme is 
widely used to assess angiographic outcomes, it is limited by poor reproducibility and its categoric 
nature. The corrected TIMI frame count (CTFC) is a simple, more objective continuous variable index 
of coronary blood flow that can be broadly and inexpensively applied. This measure of the time for dye 
to traverse a coronary artery is both accurate (highly correlated with Doppler velocity  measurements) 
and precise (reproducible). 
The method has been prospectively validated as providing independent risk stratification above 
and beyond the conventional TIMI flow grades. It has been shown to be a predictor of restenosis, and 
has been of value in elucidating the underlying pathophysiology of acute myocardial infarction. In view 
of the above and its ease of use, it is anticipated that CTFC will become a widely used method to 
evaluate coronary blood flow.(52)
Some important practical caveats exist. The measurement of CTFC from coronary angiograms 
is  a  bit  operator-dependent.  Important  variables  exist  that  significantly  affect  the  CTFC.  The  dye 
injection rate and catheter size have no effect on CTFC. However, nitrate use, heart rate, and the phase 
of the cardiac cycle in which dye is injected have a significant effect on CTFC. Therefore, studies 
comparing the CTFC need to consider these factors.(53)
Restoration  of  epicardial  flow  does  not  necessarily  lead  to  restoration  of  tissue  level  or 
microvascular  perfusion,  as  elegantly  documented  by  Ito  et  al  on  myocardial  contrast 
echocardiography.  Perfusion of  the myocardium can also be assessed using the  angiogram. In the 
Tissue Myocardial Perfusion Grade System (TMPG), TMPG 0 represents minimal or no myocardial 
blush; in TMPG 1, dye stains the myocardium, and this stain persists on the next injection; in TMPG 2, 
dye enters the myocardium but washes out slowly so that dye is strongly persistent at the end of the 
injection; and in TMPG 3, there is normal entrance and exit of dye in the myocardium.(52)
Another method of assessing myocardial perfusion on the angiogram is the myocardial blush 
grade (MBG) developed by van’t Hof et al.A grade of 0 (no blush) and a grade of 3 (normal blush) are 
the same in the TMPG and MBG systems. An MBG grade 1 or 2 represents diminished intensity in the 
myocardium and corresponds to a value of 0.5 in the expanded TMPG grading system. A TMPG of 1 
or a stain in the TIMI system is subsumed within the value of a 0 in the MBG system. Thus,normal 
perfusion in the myocardium carries a score of 3 in both the TMPG and MBG systems, and a closed 
muscle carries a score of 0 in both systems(52).
There  are  data  associating  abnormal  myocardial  perfusion  on  the  angiogram  with  slower 
Doppler  velocity  measurements  in  the  epicardial  artery.Does  abnormal  myocardial  perfusion  slow 
epicardial  flow,  or,  alternatively,  does  abnormal  epicardial  flow  impair  myocardial  perfusion? 
Although  there  is  likely  a  bidirectional  nature  to  any  causal  relationship  between  the  two,  after 
restoration of  full  epicardial  patency (eg,  after  the scaffolding of the lesion by intracoronary stent 
placement), it is likely that impaired myocardial perfusion may play a major role in reducing antegrade 
flow in the epicardial artery. A variety of drugs are available to treat abnormal myocardial perfusion, 
but aside from adenosine, their association with improved clinical outcomes remains largely untested.
(52)
There is the need for a simple, broadly applicable angiographic metric that takes into account 
indices of epicardial and myocardial perfusion to arriveat a single perfusion grade. The Angiographic 
Perfusion Score (APS) is the sum of the TFG (0 to 3) added to the TMPG (0 to 3) before and after PCI 
(total possible grade of 0 to 12).Failed perfusion can be defined as an APS of 0 to 3; partial perfusion, 4 
to 9; and full perfusion, 10 to 12.(52)
PROGNOSIS
Overall, once life threatening diseases are excluded (Aortic Dissection, Pulmonary Embolism 
etc.), patients with chest pain and NOCAD have an excellent long-term prognosis despite continued 
symptoms.In a large number of patients with chest pain and normal coronary angiograms,the survival 
after a 7-year follow-up was 96%.(1)About one third of the deaths, however, were cardiovascular in 
origin. As noted, several studies have shown that patients with endothelial dysfunction are at risk for 
subsequent cardiac events and it is this subpopulation that may contribute to the cardiac mortality seen 
in patients with chest pain and NOCAD.
CHEST PAIN CLINIC
The  difficulty  and  extensive  resource  utilization  in  diagnosing  and  treating  patients  with 
NOCAD  has  led  many  institutions  to  develop  a  specialized  chest  pain  clinic,  which  utilizes  a 
multidisciplinary approach to patient care. This allows thorough investigation, patient education, and 
frequent follow-up. Patients undergo lifestyle modification counseling and meet with dieticians and 
tobacco cessation specialists  as needed.  Patients  with NOCAD and chest  pain often have ongoing 
symptoms  and  may require  frequent  follow-  up  to  avoid  further  hospitalizations  and  unnecessary 
evaluations. This can be accomplished with the utilization of a chest pain clinic.
In today’s era of the informed patient, reassurance is usually not adequate and patients will want 
an explanation as to why they have chest pain. Without a sincere attempt to make a diagnosis, most 
patients remain frustrated and return to seek medical care.Educational opportunities, multidisciplinary 
personnel, and regular follow-up are key benefits of a chest pain clinic that may reduce health care 
utilization and improve patient satisfaction
SUMMING UP
The diagnosis and treatment of patients with NOCAD can be a complex and time consuming 
responsibility. A logical classification and step-wise approach is needed to avoid significant expense 
and unnecessary testing. The prognosis for these patients, with few excepted diagnoses, is quite good 
and reassurance, education, and follow-up are important in their management (Figure 1).
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Figure 1
                                              LITERATURE REVIEW
Literature search was conducted with the help of the Internet scientific search engine Scirus @ 
www.scirus.com (Elsevier Inc) from their start dates until December 2006 for study using specific key 
words  “Coronary  Slow  Flow  Phenomenon”,”Non  Obstructive  Coronary  Artery  Disease”  and 
“Corrected  TIMI  frame  count”.The  relevant  literature  was  sourced  from online   as  well  as  print 
versions.
The literature was classified for study purpose depending on the source and relevance to study 
in  to  1)  Relevant  standard  text-book  chapters,2)Periodical  material  which  was  sub-divided  in  to 
a)Review articles on CSFP, b)Review articles  on CTFC methodology,c)Original papers on various 
niche problems associated with CSFP,finally d) Review article on approach to patient with NOCAD, 
and  3) Relevant full text clinical practice guidelines published by a contemporary leading professional 
society.
Cardiologists are familiar with the phenomenon of slow progression of angiographic contrast in 
the coronary arteries in the absence of stenosis in the epicardial vessels in some patients presenting 
with chest pain.
The coronary slow flow phenomenon (CSFP), first described in 1972 by Tambe et al.remains 
scantily studied.(3,9)This  phenomenon should be distinguished from occurrence  of  slow flow in  the 
context of coronary reperfusion therapy such as angioplasty or thrombolysis that is associated with 
different pathophysiological and clinical implications. Similarly, coronary slow flow associated with 
coronary artery spasm,  coronary artery ectasia,  myocardial  dysfunction,  valvular  heart  disease and 
certain connective tissue disorders involving coronary microvasculature is easy to understand.(4,10)CSFP 
may occasionally also result from inadvertent air-embolism during angiography or may be due to an 
overlooked ostial lesion. 
However, it is not certain whether CSFP in the absence of any of these known causes represents 
merely an angiographic curiosity or has special physiologic or therapeutic implications. 
Overall, CSFP is observed in approximately 1% of the patients undergoing CAG, especially in 
patients  presenting  with  acute  coronary  syndrome.  In  the  Thrombolysis  In  Myocardial  Infarction 
(TIMI)-IIIA  study,  4%  of  patients  presenting  as  unstable  angina  but  with  normal  /  insignificant 
epicardial coronary artery disease (CAD) showed impaired angiographic filling suggestive of CSFP.(5) 
Mangieri et al.(6)reported an incidence of 7% of this phenomenon in patients suspected to have CAD, 
however the documentation of slow flow was visual without any objective criteria.
Usually TIMI flow grade scheme is followed to assess coronary blood flow. It reflects the speed 
and completeness of the passage of the injected contrast through the coronary artery.(7,8)This method is 
a qualitative way of assessing coronary flow and is limited by significant inter-observer variability. In 
contrast, corrected TIMI frame count (CTFC) is a more quantitative and reproducible index of coronary 
artery flow.(51,52)It represents the number of cine frames required for contrast to reach the standardized 
distal coronary artery landmarks. CSFP is defined as CTFC greater than 2 standard deviations (SD) 
from normal published range for that particular vessel.(51,52)
CSFP is more often seen in males who are current smokers.(11)This is in contrast to “Cardiac 
syndrome X” which is predominantly a disorder of post-menopausal females.(11)Patients with CSFP 
more  often  present  with  rest  pains,  requiring  urgent  hospital  admission.  Both  resting 
electrocardiographic (ECG) abnormalities as well as positive Treadmill Test (TMT) are more frequent 
in patients with slow flow as compared with patients having normal coronary flow.
Myocardial perfusion scintigraphy shows reversible perfusion abnormalities in 30-75% of such 
patients.(12,13)On long-term  follow-up  the  clinical  course  is  usually  benign  in  patients  with  CSFP, 
although it is frequently punctuated with remitting, relapsing anginal episodes resulting in considerable 
impairment in quality of life.(14)Over 80% of these patients experience recurrent chest pain and one 
third of them require readmission for an acute exacerbation.(15)Occasionally, patients may present with 
evidence of acute myocardial infarction.(16)
Recently, Atak et al.(17)have reported abnormalities of corrected QTdispersion in patients with 
CSFP. Whether this predisposes to ventricular arrhythmias and sudden cardiac death in these patients is 
not clear.
The pathophysiological mechanisms of CSFP remain uncertain. Several hypotheses however, 
have  been  suggested  for  slow  coronary  flow  phenomenon,  including  a  form  of  early  phase  of 
atherosclerosis,  small  vessel  dysfunction,  Hagen–Poiseuille’s  equation  model,  imbalance  between 
vasoconstrictor and vasodilatory factors, and platelet function disorder. More recently, there has been 
mounting evidence that inflammation plays an important role in the initiation,  development as well as 
evolution of atherosclerosis, suggesting that atherosclerosis is an inflammatory disease. New evidence 
has  also  indicated  that  inflammation  may be  involved  in  the  development  of  slow coronary flow 
phenomenon.(2) 
The coronary circulation is traditionally considered as a two-tier model. The first tier   consists 
of epicardial vessels, which are also referred to as “conductance vessels” as these do not pose any 
resistance to blood flow. The second tier consists of “small vessels” of <400 μm (“resistive vessels”) 
which primarily regulate myocardial blood flow in the absence of any significant obstructive epicardial 
stenosis.(18)
 “Small vessel dysfunction” has been typically implicated in the pathogenesis of CSFP since its 
first description.The evidence of affliction of small vessels comes from the results of histopathological 
examination  of  ventricular  biopsy  specimens  in  patients  with  CSFP.(6,19)Mosseri  et  al.(19) reported 
abnormalities of small coronary arteries along with myocardial hypertrophy and patchy fibrosis in the 
biopsy samples from right ventricle of six patients with CSFP. However, majority of these patients had 
concomitant diseases that could have induced these changes. 
Later,  Mangieri  et  al.(6)reported  histopathological  examination  of  left  ventricular 
endomyocardial biopsy specimens in a more homogenous group of 10 patients of CSFP who did not 
have  any  other  cardiac  or  systemic  diseases.  There  was  evidence  of  small  vessel  affliction  i.e. 
endothelial thickening due to cell edema, capillary damage and reduced luminal diameter of the small 
vessels. 
Electron  microscopy revealed  irregular  nuclear  morphology and several  indentations  of  the 
nucleolemma and pyknosis. But it is not certain whether slow flow 
leads to these histopathological changes or whether these changes cause slow flow, though the later 
appears more likely.(12)Also, these fixed structural changes cannot explain the acute presentation in the 
majority of these patients. 
The  clinical  and  angiographic  variability  implies  a  significant  dynamic  component  to  the 
coronary microvascular resistance. It is noteworthy that only a third of the patients with CSFP fulfilled 
the criteria on a repeat angiographic study.(15)Thus CSFP lacks reproducibility.It is postulated that this 
dynamic increase in microvascular tone is due to “microvascular spasm” resulting in recurrence of 
symptoms.  Exact  mechanism for  this  dynamic response  is  not  well  elucidated.  It  is  plausible  that 
intermittent release of certain autacoids (neuropeptide-Y, endothelin-1, thromboxane-A2 etc.) mediate 
coronary vasoconstriction.(15,20-22)
Even invasive hemodynamic and metabolic parameters do not consistently suggest a uniform 
mechanism for CSFP. Resting hemodynamic parameters of heart rate, blood pressure or the double 
product fail to explain the occurrence of CSFP.(13,15)The vasodilatory response of the microvasculature 
to provocative stimuli is less clear and has evoked mixed responses.(15,23)Lower resting coronary sinus 
oxygen saturation has been observed in  patients  with CSFP as  compared to  controls  for  a  similar 
myocardial oxygen demand.(15)This implies a higher transcoronary myocardial extraction caused by the 
delayed resting coronary perfusion consistent with CSFP. Whether this delayed perfusion results in 
myocardial ischemia either during rest or during stress needs to be addressed. 
Yaymaci et al.(24)investigated the presence of stress-induced myocardial  ischemia in patients 
with  CSFP  by  measuring  two  metabolic  indicators  of 
ischemia  i.e.  coronary  arteriovenous  oxygen  content  difference   and  lactate  production.  Although 
majority of patients developed anginal pain with atrial pacing, only few (17%) revealed evidence of 
metabolic  ischemia.  Thus,  angina  pectoris  in  most  patients  with  CSFP  does  not  originate  from 
myocardial ischemia as demonstrated by metabolic parameters. However, of the subset of patients who 
showed  evidence  of  metabolic  ischemia,  majority  showed  a  perfusion  defect  using  single  photon 
emission computed tomography (SPECT) that anatomically correlated well with the vessel showing 
CSFP. These differences in patients with CSFP may be explained by the variability in the degree of 
coronary flow reserve (CFR), which, per say, is an indicator of microvascular function. 
Recently, Sezgin et al.(25)reported evidence of endothelial dysfunction in patients with CSFP 
using  simple  method  of  measuring  flow-mediated  vasodilation  of  the  brachial  artery.  It  has  been 
suggested  that  flow-mediated  vasodilation  is  predominantly  due  to  endothelial  release  of  nitric 
oxide.There was a strong and inverse relationship between CTFC and percentage of flow-mediated 
vasodilation in patients with CSFP thereby suggesting that endothelial nitric oxide activity is impaired 
in these patients.(25)
It is well appreciated that diffuse atherosclerosis may be present in angiographically normal 
appearing  vessel.  Further,  macro-  and  microvascular  disease  may  also  coexist.(26,27)A recent  study 
investigated  the  significance  of  epicardial  vessel  affliction  by  studying  coronary  anatomy  using 
intravascular ultrasound (IVUS) and measuringepicardial resistance using fractional flow reserve (FFR) 
in patients with CSFP.(27)FFR is an index of resistance to flow along the epicardial vessel and is defined 
as the ratio of distal to proximal coronary pressures.(18)In maximal hyperemia (e.g. adenosine-induced), 
FFR is independent from microvascular bed. If there is no resistance along the artery as expected in 
normal epicardial artery, there is no pressure decline and FFR approaches unity. Surprisingly, a decline 
in  the  distal  coronary pressure  leading  to  significantly  lower  FFR value  was  seen  in  the  patients 
exhibiting slow flow phenomenon. 
There was a strong negative correlation between CTFC and FFR. Interestingly,  the patients 
showing perfusion defects using myocardial perfusion scintigraphy had significantly lower FFR values, 
signifying even higher epicardial  resistance.  There was diffuse intimal  thickening and calcification 
throughout  the  epicardial  arteries  on  IVUS.  A negative  correlation  was  observed  between  intimal 
thickness and FFR. It is postulated that decreased FFR levels are due to increased resistance in the 
epicardial coronary arteries resulting from diffuse atherosclerotic disease as demonstrated by IVUS.(27) 
Thus,  at  present,  the  data  are  not  sufficient  to  delineate  the  borders  of  this  phenomenon. 
Whether it  is  due to involvement of predominantly macro- or microvasculature of the heart  is not 
certain.  It  is  hypothesized  that  CSFP  may  be  a  form  of  early  phase  of  atherosclerosis  in  some 
patients.However, certain other factors may also contribute to CSFP.
It  appears  that  CSFP may represent  a heterogeneous group of disorders unified because of 
characteristic  angiographic  appearance.  Slow  flow  has  been  characteristically  seen  in  ectatic  and 
aneurysmally dilated coronary arteries (dilated 
coronaropathy) with proportionately more impairment of blood flow in these vessels with increasing 
coronary artery diameters.(28)This is in accordance with the Hagen-Poiseuille’s equation which states 
that resistance to flow within a tube depends on the dimensions of the tube and the viscosity of the fluid 
in it.(29)
However, the relationship of CSFP in relation to vessel diameter has not been well studied. 
Furthermore,importance  of  other  rheological  factors,  blood  viscosity,  fibrinogen  levels  and 
hyperlipidemia  (contributing  to  increased  blood  viscosity)  in  these  patients  has  not  been  studied. 
Hematocrit and fibrinogen are the major determinants of blood viscosity. Increased blood viscosity 
leading to decrease in coronary blood flow reserve has been associated with hyperlipidemia and high 
fibrinogen levels.(29,30)The therapeutic implications, if any, of these findings remain to be studied.
Other rare causes may be important in appropriate settings. For example, slow coronary filling 
has been reported in patients with cocaine use even in the absence of coronary artery spasm.(31)
Endothelin-1and Nitric oxide are important molecules that modulate vasodilatory response to 
stress (rapid atrial pacing/exercise). Recently published studies have highlighted the imbalance between 
Endothelin-1 and Nitric oxide release in patients  with CSFP as compared to  controls  with normal 
coronary flow.(32,33)No significant difference in arterial and coronary sinus Nitric oxide plasma levels 
was seen in the two groups, at baseline as well as after pacing. In contrast, basal plasma Endothelin-1 
levels were higher in patients with CSFP. Rapid atrial pacing resulted in significantly higher coronary 
sinus levels of Endothelin-1 in patients with CSFP, which also correlated well with the CTFC. 
Furthermore,  in  patients  with  CSFP,  coronary  sinus  Endothelin-1  levels  also  increased 
significantly  as  compared  to  femoral  artery  Endothelin-1  levels.  Even  correlation  of  Endothelin-1 
levels and intimal thickness of coronary artery using IVUS has been reported.(32)It is possible that CSFP 
results from imbalance of Endothelin-1, a potent vasoconstrictor leading to deregulation of vascular 
tone  even  in  the  very early  stages  of  plaque  formation.  More  studies  are  required  to  unravel  the 
molecular mechanisms of CSFP.
There are no definite treatment modalities for patients with CSFP. Conventional antianginal 
therapy is of limited value in the chronic management in these patients.(34)Nitrates are ineffective as 
their biotransformation to active metabolite is diminished due to deficiency of required enzymes in 
coronary microvessels as compared to larger epicardial coronary arteries.(35,36)
In contrast, dipyridamole may be effective due to its predominant action on the small vessels of 
diameter  less  than  200  μm.  It  blocks  uptake  of  adenosine  by  both  vascular  endothelium  and 
erythrocytes  and  prevents  its  conversion  to  inactive  metabolites.  This  results  in  re-distribution  of 
vascular resistances due to vasodilation of the small vessels.(36,37)
Mangieri et al.(6)demonstrated the effectiveness of dipyridamole in acute setting during coronary 
angiography in patients with CSFP.
Intracoronary administration of this drug relieved microvascular tone and accelerated contrast 
run-off in coronary arteries without changing the diameter of epicardial coronary vessels. As expected, 
intracoronary nitroglycerine failed to produce any beneficial effect in these patients. Demirkol et al.
(12)also observed improvement in myocardial perfusion with dipyridamole infusion using myocardial 
perfusion Single Photon Emission Computed Tomography. 
Long-term oral therapy with dipyridamole was assessed by Kurtoglu and associates(38)  in an 
open-label fashion. Coronary flow returned to normal levels in majority of the vessels as adjudged by 
using CTFC. This was accompanied with complete relief from chest pain in two-third of patients and 
decrease in symptoms in the remaining. Since this phenomenon, per say, is punctuated by remissions in 
clinical course, more data using case control studies are required to confirm the above observations.
Conventional  calcium  L-channel  blockers  (diltiazem/  verapamil)  are  of  limited  value  in 
alleviating symptoms. This is  perhaps  due to absence of voltage-gated L-type calcium channels in 
microvessels, as shown by studies in the animalmodels.(39)Instead, the microvascular tone may appear 
to rely on other types of voltage-gated calcium channels, possibly of the T-type.(40)Mibefradil is a long-
acting  calcium  T-channel  antagonist  that  was  approved  by  FDA  in  1997  for  the  treatment  of 
hypertension and chronic stable angina pectoris. Unfortunately the drug was voluntarily withdrawn 
shortly after its launch due to its numerous clinically relevant drug interactions.(41)
Recently, Beltrame et al.(34)assessed the acute and long-term clinical benefits of mibefradil in 
patients with CSFP by exploring its beneficial effects on microvessels. There was significant acute 
angiographic  improvement  in  coronary  flow  indices  with  this  drug.  CSFP  was  abolished  in 
approximately three fourth of the vessels at 30 min after the drug intake. This occurred without any 
significant changes in the epicardial vessel diameter or rate-pressure product.
Interestingly,  the  improvement  in  flow indices  occurred primarily in  vessels  with CSFP as 
compared to vessels with normal epicardial flow. In accordance with these acute angiographic results, 
long-term clinical benefits with this drug were also observed. In a randomized, double blind, placebo 
controlled, cross-over study, there was substantial reduction in frequency of angina by 56% (p<0.001), 
episodes of prolonged angina by 74% (p<0.001), and sublingual nitrate consumption by 59% (p<0.01) 
along with  improvement  in  physical  quality of  life  (p=0.003).(34)Since  the  drug  has  been  formally 
withdrawn, these observations may stimulate further research with similar molecules.
Recently, a three-dimensional pharmacophore model consisting of three hydrophobic regions, 
one  hydrogen  bond  acceptor  and  one  positive  ionizable  region  has  been  hypothesized  for  T-type 
calcium channel blockers.(42)  Whether it acts as a valuable tool in designing new ligands for this group 
of drugs remains to be seen. 
Thus,CSFP continues to intrigue the clinicians. It appears to represent a heterogeneous group of 
disorders. In some it may represent an early stage of atherosclerosis with endothelial dysfunction and in 
others it may indicate microvascular dysfunction or other unknown disorders. The prognosis appears 
good although symptoms tend to recur.  Further advances in the understanding of pathophysiologic 
mechanisms and treatment of CSFP are awaited.
AIM & OBJECTIVE
AIM
This  study  addresses  a  major  problem  of  contemporary  cardiology.In  the 
cardiovascular  out-patient  department,we  commonly  see  patients  presenting  with  angina 
pectoris,during the disease attack angiographically normal coronary arteries were eventually 
demonstrated.  These patients  are  usually characterized by the  following  clinical  features: 
usually young,angina pectoris for a long duration without other accompanying cardiovascular 
disease but significant slow coronary distal flow in one or multiple vessels.
The mechanism for this clinical setting of coronary artery disease is unclear,but the 
patients  have  commonly  large  epicardial  coronary  arteries,  which  may  suggest  a 
hemodynamic mechanism of coronary disorder.Evincing a keen interest in the phenomenon,it 
was investigated further and hence this study.
Only  a  limited  number  of  studies  have  focused  on  the  etiology  of  this  unique 
angiographic phenomenon.Four clinical types of Coronary Artery Disease (CAD) have been 
classically defined, that is,chronic stable angina pectoris (CSA),variant angina pectoris,silent 
angina pectoris and cardiac syndrome X.
However patients presenting with coronary slow flow phenomenon in NOCAD are hard 
to be classified into one of these.Whether this  is really a new kind of coronary disease is  still 
unknown and deserves further investigation.It is suggested that these patients may be reclassified into a 
new clinical entity called as ‘‘Coronary Slow Flow Syndrome’’.
OBJECTIVE
It  has been an interesting journey from “Coronary Slow Flow - An angiographic curiosity” 
through “Coronary Slow Flow Phenomenon – A recognized angiographic entity in Non Obstructive 
Coronary Artery Disease” to “Coronary Slow Flow Syndrome - A novel Non Obstructive Coronary 
Artery Disease ?”  In this study it is hypothesized that “Coronary slow flow syndrome” is a novel 
subset of Non Obstructive Coronary Artery Disease with distinct features.To prove the hypothesis it is 
aimed  to  study  the  Coronary  Artery  Disease  characteristics  peculiar  to  ‘‘Coronary  Slow  Flow 
Phenomenon” in a population of patients with Non Obstructive Coronary Artery Disease.It is  intended 
to achieve the aim through a set of objectives which permit a comparison of disease characteristics of 
the slow flow group with that of a control group having normal flow.
The  objective of the study may be crystallized in to the following :            
1. Compare and analyze the demographic characteristics,clinical features,Coronary Artery Disease 
risk factor profile,anti anginal medication profile of coronary slow       flow versus normal flow 
in patients with Non Obstructive Coronary Artery  Disease, 
2. Compare and contrast total work load,total exercise duration and ECG  parameters of maximum 
ST depression,time to onset of ST depression,time to offset of ST depression on Tread Mill Test 
of coronary slow flow versus  normal flow in patients with Non Obstructive Coronary Artery 
Disease,
3. Follow up patients with coronary slow flow and normal flow in a Non Obstructive Coronary 
Artery Disease population for detection of  “anginal episode” and “hospitalization for angina” 
as the end point.
                                            METHODOLOGY
1. Setting
The setting is the Cardiology Department of a tertiary level teaching hospital in a metropolitan 
city.
2. Study design
This is an descriptive and an observational,case-controlled comparative cum prospective cohort 
study.(55)
3. Study period
This study was carried over a period of two years from January 2005 to December 2006.
4. Study population
The study population was composed of patients with CAD.CAD was defined as patients with 
known stable chronic CAD on anti-anginal therapy,attending the out-patient clinic of the Cardiology 
Department.
5. Inclusion criteria 
The inclusion criteria was consecutive patients in the study population during the time-period 
January 1st 2005 to December 31st 2006,who underwent TMT and subsequent Coronary angiography at 
our department and were found to have NOCAD.NOCAD was defined for study purposes as CAD 
patients with absolutely normal epicardial coronary arteries without any obstructive or non-obstructive 
lesion  on  routine  conventional  coronary  angiography.TMT  and  Coronary  angiography  was 
performed because subjects enrolled in the study had CAD which could not be adequately 
clarified on the basis of physical diagnosis alone.  (43,44) ACC/AHA practice guidelines were 
adhered to in evaluating the CAD patients with TMT and Coronary angiography.(43)
There are two groups in this study : A group having NOCAD and slow flow (Group I) and a 
control group of NOCAD with normal flow.(Group II).
6. Exclusion criteria
Patients  in  the  study population  with  recent  /  past  acute  coronary syndrome,valvular  heart 
disease,pericardial  disease,prosthetic  heart  valve,  infective  endocarditis,  mitral  valve  prolapse, 
hypertrophic,  restrictive  and  dilated  cardiomyopathy,  left  ventricular  hypertrophy,right  ventricular 
hypertrophy, heart failure,major supraventricular and ventricular cardiac arrhythmia,connective tissue 
disease,pulmonary,  renal,hepatic  and  hematological  disorder,resting  ECG  changes  and  ECHO 
abnormalities were excluded from the study.(44) 
7. Study end points
The end point of the prospective-cohort component is “anginal episode” on follow-up which in 
this study is prospectively defined as    1) Substernal chest discomfort with a characteristic quality and 
duration that is 2) provoked by exertion or emotional stress and 3) relieved by rest or nitrates.(43)
The end point of the case-controlled comparative component is the clinical and TMT profile 
namely  demographic  distribution,coronary risk  profile,anti-anginal  medication  profile,total  exercise 
duration,maximum  work  load,maximum  ST  segment  depression,time  to  onset  of  ST  segment 
depression and duration of ST segment depression in to recovery.
Angiographic end point as a stand alone descriptive component constitutes the characterization 
of CSFP in a typical South Asian population.                                                                  
8. Clinical Assessment
Extracardiac  causes  of  chest  pain  such  as  musculoskeletal  and  gastrointestinal 
disorders were eliminated in all the patients. Case records were reviewed for detailed history, 
physical  examination,  relevant  biochemical  tests,resting  ECG  and  transthoracic 
echocardiography (ECHO) data.Atherosclerotic risk factor profile,current anti-anginal therapy-
nitrates,beta blockers and calcium channel blockers,patient’s body mass index (BMI), blood 
pressure  (BP)  ,  and  pulse  rate  (PR)  were  also  recorded.Angina   pectoris  was  graded 
according to the Canadian Cardiovascular Society (CCS) grading.All other data was acquired 
as per contemporary diagnostic criteria.The data was duly entered in a proforma specially 
designed for study purpose.
9.Follow-up
At  follow-up,30  days  after  the  date  of  coronary  angiography  all  subjects  were 
specifically enquired for the occurrence and frequency of anginal attacks and hospitalization 
for the same if any.
10.TMT 
Each included subject  underwent  a  standard TMT according to  the Bruce protocol 
using Esaote Formula system (Esaote SpA,Italy).ECG Criteria for positivity were horizontal or 
downsloping ST-segment depression of ≥1 millimetres(mm.) at 80 milliseconds after the J 
point during exercise or recovery in two or more contiguous leads for study purpose.Total 
exercise time in seconds(s), Total workload in metabolic equivalents (METS),Time to onset of 
ST-segment  depression  in  seconds(s),Magnitude  of  ST-segment  depression  in 
millimeters(mm) and Time to offset of ST-segment depression in seconds (s) were noted.(45)
11. CAG and documentation of CTFC 
Subjects  underwent  selective  coronary  angiography  via  the  femoral  route  using  standard 
Judkins technique.(46-50) Coronary arteries were visualized in left and right oblique planes, and cranial 
and  caudal  angles using  Philips  Integris  HM 3000 model  cine angiography system (Philips 
Medical Systems Nederland BV, Eindhoven, Netherland).Injection of contrast medium,Urograffin 
(Ultravist-370; Schering AG, Berlin, Germany) was carried out by hand injection, at a speed of 3–4 
mL/s for left coronary artery and 2–3 mL/s for right.Coronary arteriography was recorded at a speed of 
12.5 frames per second (fps).CTFC was measured with a frame counter using HCP DICOM Net MFC 
Application version 4.0 40.0 (SoftLink International Pvt.Ltd).
12. CTFC Methodology 
For  nearly  2  decades  now,  the  Thrombolysis  In  Myocardial  Infarction  (TIMI)  flow  grade 
classification scheme (TFG) has been successfully used to assess coronaryblood flow in acute coronary 
syndromes. It has been a valuable tool to compare angiographic outcomes following reperfusion, and 
the association of the TFG with clinical outcome (including mortality) has been well documented.The 
relationship between flow grade and mortality does satisfy what some consider to be 3 criteria required 
to validate a surrogate end point for mortality, as follows: (1) There is an association between TIMI 
grade 3 flow and mortality, (2) an agent such as recombinant tissue plasminogen activator improves 
TIMI  grade  3  flow  by  22%  over  another  agent  such  as  streptokinase,  and  (3)  the  agent  tissue 
plasminogen activator improves mortality 1.1% over streptokinase.(51-52)
Although the TFG classification scheme has been a valuable tool for comparing the efficacy of 
reperfusion strategies and in the identification of patients at higher risk for adverse outcomes in acute 
coronary syndrome, there are limitations to this classification scheme.To overcome these limitations,a 
new, more objective and precise index of coronary blood flow called the corrected TIMI frame count 
(CTFC) was developed, in which the number of cine frames required for dye to reach standardized 
distal landmarks are counted; this is essentially a measure of the time for dye to go down the artery.
Coronary flow was quantified objectively by two independent observers, who were blinded to 
the clinical details of the individual participants, using the CTFC method as described by Gibson et 
al.(51)In our center, cinefilming is performed at 12.5 fps. Therefore, a correction has to be made for this 
difference by multiplying the CTFC observed in these films by a factor of 30 divided by the actual 
number of frames filmed per second. After assessement of coronary flow in the coronary arteries using 
the CTFC method, for each group the mean CTFC,which is the mean value of the frame count in the 
LAD, LCX, and RCA, was obtained from the two groups. Coronary angiograms were  analyzed by two 
blinded observers and their joint opinion was used as an inclusion criteria.
The first  frame was defined by a column of contrast  extending across >70% of the arterial 
lumen in  anterograde motion.   In the first  frame used for  TIMI frame counting,  a  column of  dye 
touches both borders of the coronary artery and moves forward.In the last frame, dye begins to enter 
(but does not necessarily fill)  a standard distal landmark in the artery,(Figures 2-3).These standard 
distal landmarks are as follows: in the RCA, the first branch of the posterolateral artery(PLV); in the 
circumflex system, the most distal branch of the obtuse marginal branch(OM) and in the LAD, the 
distal bifurcation, which is also known as the “moustache,” “pitchfork” or “whale’s tail”. 
                             
                                             
Figure 2  Definitions of the first  and last frames used for TIMI frame counting. The first  frame used for TIMI frame 
counting is the first frame in which dye fully enters the artery. This occurs when three criteria are met: (1) A column of 
nearly full or fully concentrated dye must extend across the entire width of the origin of the artery; (2) Dye must touch both 
borders of the origin of the artery; and (3) There must be antegrade motion to the dye. Dye may initially track down a single 
wall of the artery as it leaks from the catheter before the injection, and these frames are not included in the TIMI frame 
count.  If the LAD is subselectively engaged and the LCX is the culprit vessel, the TIMI frame count begins when dye first  
touches both borders at the origin of the LCX. The same rule holds for subselective engagement of the circumflex artery. 
The last frame counted is the one in which dye first enters the end-point branch off the target artery. Note that complete 
opacification of the target artery is not required, just initial entry of dye into the culprit artery. Often, the last frame is best 
determined by running the cinefilm past the initial opacification of the end-point branch and then moving frame-by-frame in 
reverse  until  the  end-point  branch  disappears.  Care  must  be  taken  to  advance  one  more  frame forward  once  the  dye 
disappears  to  identify  the  frame  in  which  dye  first  appears.               
  
  
Figure  3  TIMI frame-counting method.In the first frame (lower left panel), a column of near or fully concentrated dye 
touches both borders of the coronary artery and moves forward. In the last frame (second column), dye begins to enter (but 
does not necessarily fill) a standard distal landmark in the artery.These standard distal landmarks are as follows: the first 
branch of the posterolateral artery in the RCA (third column,top panel); in the circumflex system, the most distal branch of 
the obtuse marginal branch that includes the culprit lesion in the dye path (third column ,middle panel); and in the LAD the 
distal bifurcation, which is also known as the moustache, pitchfork, or whale’s tail (third column,  bottom panel).
                                           The normal frame counts for the left anterior descending (LAD) coronary artery 
are 1.7 times greater than the mean for the left circumflex (LCX) coronary artery and the right coronary 
artery (RCA). Hence, the longer LAD frame counts were corrected by dividing by 1.7 to derive the 
CTFC. The CTFC of LAD was assessed in either the right anterior oblique view with caudal angulation 
or the left anterior oblique view with cranial angulation and that of LCX and RCA in straight left 
anterior oblique views.
In multiple studies, the CTFC has been shown to be quite reproducible with a 1- to 2-frame 
difference between observers.The CTFC is also accurate in that it is highly correlated with Doppler 
velocity wire measure of CFR, distal velocity, average peak velocity, and volumetric flow,as well as 
FFR.Normally 21 frames are required for dye to traverse the human coronary artery.Despite differences 
in the length of the coronary arteries, the force of injections, the diameter of the arteries, heart rates, 
cardiac output, and catheter engagement, there is only a 3.1-frame standard deviation among patients 
with normal flow, and the 95% confidence interval for normal flow extends from >14 frames to < 28 
frames.
In contrast to the conventional TIMI flow grade system, the CTFC is quantitative rather than 
qualitative,  is  a  continuous  rather  than a  categorical  variable,  and  is  objective,  reproducible,  and 
sensitive to flow changes.This simple index of coronary flow allows calibration or standardization of 
flow grading and should facilitate comparisons of flow data between angiographic trials.(51-54)
13. Definition of normal coronary flow and slow coronary flow
All participants with a CTFC greater than two SD from the normal published range for the 
particular vessel were accepted as having slow flow while those who have CTFC that fell within the 
SD of the published normal range for a population of patients with NOCAD were considered to have 
normal coronary flow. The  cutoff values for NOCAD were, defined according to TIMI frame count 
method  by  Gibson  et  al.:  36.2  ±  2.6  frames  for  left  anterior  descending,  22.2  ±  4.1  frames  for 
circumflex and 20.4 ± 3.0 frames for right coronary artery. The corrected cutoff value for LAD was 
21.3 ± 1.5 frames.(51) 
14. Statistical analysis
Statistical  analyses  were  performed with  SPSS version  14.0  for  Windows(Chicago 
IL).All  continuous variables were normally distributed are expressed as arithmetic  mean  ±  SD and 
categorical variables as percentage. The acquired data was summarized in to relevant tables and 
graphs.
2-tailed  students  t  test  was  used  to  compare  the  group  arithmetic  means  of  the  normally 
distributed continuous variables and for categorical data, Chi-Square test was used.The null hypothesis 
was rejected at the 95% confidence interval,considering a probability value of  p < 0.05 as statistically 
significant.(55)
               
RESULT
During  the  study period  1957  coronary  angiograms  were  performed  in  our  Cardiovascular 
catheterization  laboratory.107  consecutive  NOCAD  patients  in  this  period  constituted  the  study 
subjects.
57 patients  with  angiographically documented CSFP at  least  in  1  major  epicardial 
coronary artery and otherwise normal coronary arteries formed the study group.These patients 
were compared with an angiographic control group consisting of the remaining 50 patients found to 
have absolutely normal coronary arteries with normal coronary flow.
1. Clinical characteristics of study population :
In group I there were 42 males (73%) and 15 females (37%).Group II on the other hand had 22 
males (44%) and 28 females (56%).The mean age of slow flow subjects was 54.8 ± 13.8 and that of 
normal flow 55.7 ± 14.9.The mean  BMI was 28.6 ± 4.2 in the slow flow group and 27.9 ± 3.9 in the 
normal  flow,(Table  1).The  difference  in  sex  distribution  between  the  two  groups  was  statistically 
significant.
                                                                 Table 1
CLINICAL
VARIABLE
GROUP-I
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
AGE 54.8 ± 13.8  55.7 ± 14.9          0.63
MALE / FEMALE 42 / 15(73 / 27) %  22 / 28(44/56) %       < 0.01
BODY MASS INDEX 28.6 ± 4.2  27.9 ± 3.9          0.53
Age in years,Body Mass Index in kg/m2
2. Hemodynamic characteristics of study population :
Baseline blood pressure – systolic and diastolic and pulse rate is depicted in Table 2.The mean 
PR in slow flow group was 67.2 ± 7.2 and 71.3 ± 8.2 in the control group.The mean BP was 132.6 ± 
8.4 and 84.2 ± 9.6 in slow flow group,128.7 ± 9.7 systolic and  82.4 ± 8.5 diastolic in the normal flow 
group,(Table  2).The  difference  in  the  baseline  hemodynamic  state  between  the  two  groups  was 
statistically insignificant.  
                                                                  Table 2
HEMODYNAMIC
VARIABLE
GROUP-I
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
PULSE RATE      67.2 ± 7.2      71.3 ± 8.2          0.46
SYSTOLIC BP    132.6 ± 8.4    128.7 ± 9.7          0.65
DIASTOLIC BP      84.2 ± 9.6      82.4 ± 8.5          0.45
Pulse Rate in beats per minute,Blood Pressure in mmHg
3. Risk factor profile of study population :
78 % of slow flow group patients were hypertensive versus only 56 % of the control group.The 
prevalence of diabetes mellitus in the two groups was 68% and 70 % for the slow flow and control 
groups respectively.64 % of slow group were dyslipidaemic versus 62 % of the normal flow group.An 
overwhelming 73 % of the slow flow population were active smokers while only 52 % of the normal 
flow actively smoked.Family history of CAD was elicited in 60 % of the slow flow patients while only 
44 % of the normal flow group had a family history of CAD.(Table 3).The 
difference  in  the  proportion  of  patients  with  risk  factors  for  CAD  between  the  two  groups  was 
statistically significant for hypertension,smoking and family history. 
                                                                  Table 3
RISK FACTOR
VARIABLE
GROUP-I
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
HYPERTENSION          44 (78%)          28 (56%)        <0.01
DIABETES MELLITUS          38 (68%)          34 (70%)          0.42
DYSLIPIDEMIA          36 (64%)          31 (62%)          0.63
SMOKING          41 (73%)          22 (44%)        <0.01
FAMILY HISTORY          34 (60%)          22 (44%)        <0.01
Number (%) of patients with the CAD risk factors
4. Anti-anginal medication profile of study population :
Review of current patient prescription for anti anginal therapy revealed that 100 % of patients 
with both slow flow and normal flow received at least one class of anti-anginal agents.76 % of slow 
flow patients recieved at least two classes of  anti anginals while 70 % of the normal flow patients 
received the same.Considering three classes of anti anginals it was 64 % for the slow flow group versus 
32 % for the normal flow group.The difference in the proportion of patients on three classes of anti 
anginals between the two groups was statistically significant,(Table 4)   
                                                              Table 4
MEDICATION
CLASS VARIABLE
GROUP-I
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
ONE CLASS     57 (100%)        50 (100%)         0.76
TWO CLASSES     44 (76%)      30 (70%)         0.64
THREE CLASSES     37 (64%)      16 (32%)       <0.01
Number (%) of patients with at least one,two or three classes of  anti  anginal medication in 
current physician prescription – Nitrates,Beta Blockers,Calcium Channel Blockers,One Class – 
Nitrates alone,Two Classes – Nitrates and Beta Blockers or Calcium Channel Blockers,Three 
Classes – Nitrates,Beta Blockers and  Calcium Channel Blockers.
5. Biochemical profile of study population :                
The results of biochemical tests are depicted in Table 5.B.glucose was 98.7 ± 13.2 mg % for the 
slow flow group versus 95.6 ± 11.9 mg % for the normal flow group.Hemoglobin measured 12.8 ± 1.5 
g % in the slow flow group and  12.3 ± 1.6 g % in the normal flow group.Lipid measurements were 
127.8 ± 16.7 mg % versus 122.9 ± 18.5 mg % for LDL,44.9 ± 12.9 mg % versus 42.8 ± 13.6 mg % for 
HDL for the slow flow and normal flow groups respectively.Total Cholesterol was 192.7 ± 23.8 mg % 
for the slow flow group and 188.8 ± 43.7 mg % for the normal flow.Triglycerides measured 156.9 ± 
23.8 mg % for slow flow and 153.7 ± 22.9 mg % for normal flow.The difference between the two sets 
of variables for the slow flow and normal flow groups was statistically insignificant.
                                                                   Table 5
BIOCHEMICAL
VARIABLE
GROUP-I
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
B.GLUCOSE      98.7 ± 13.2      95.6 ± 11.9          0.43
TOTALCHOLESTEROL    192.7 ± 23.8    188.8 ± 43.7          0.56
LDL-CHOLESTEROL    127.8 ± 16.7    122.9 ± 18.5          0.86
HDL-CHOLESTEROL      44.9 ± 12.9     42.8 ± 13.6          0.76
TRIGLYCERIDES    156.9 ± 23.8    153.7 ± 22.9          0.75
HEMOGLOBIN      12.8 ± 1.5      12.3 ± 1.6          0.67
All measurements on fasting venous blood samples
Values expressed in mg / 100mL
Hemoglobin values in g / 100mL
6. TMT profile of study population :
The various measures on TMT for the two groups are tabulated in Table 6.The difference in 
total  work  load  and  maximum  exercise  duration  was  statistically  statistically  between  the  two 
groups.While average total exercise duration was 346 ± 74 seconds in the slow flow it was 443 ± 72 
seconds in the normal flow.Maximum workload between the two groups measured  9.8 ± 0.6 METS in 
the slow flow while it  was 12.4 ± 0.4 METS in the normal flow group.The differences in various 
measures of ST depression were also statistically significant between the two groups except for the 
maximum amplitude of ST depression.The time to onset of ST depression was 329 ± 64 seconds in the 
slow flow group while it averaged  421 ± 73 seconds in the normal flow group.The time to offset of ST 
depression averaged 3.8 ± 0.7 seconds in the slow flow group while it averaged 2.5 ± 0.4 seconds in the 
normal flow group.The maximum ST depression was 1.4 ± 0.6 mm in the slow flow group and 2.5 ± 
0.4 mm in the normal flow group.
                                                               Table 6                            
TMT PARAMETER
VARIABLE
GROUP-I 
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
TOTAL WORK LOAD       9.8 ± 0.6               12.3 ± 0.4       < 0.05
TOTAL EXE. DUR.      346 ± 74                443 ± 72       < 0.05
MAXIMUM ST ↓       1.4 ± 0.4                1.2 ± 0.2          0.51
TIME  TO ONSET OF ST ↓      329 ± 64               421 ± 73       < 0.01
TIME TO OFFSET OF ST ↓       515 ± 26               390 ± 31       < 0.05
Total Work Load - in Metabolic Equivalents (METS) - mL/kg/minute,
Total Exe. Dur. - Total Exercise Duration in seconds,
Maximum ST↓- Maximum ST segment depression in millimeters,
Time to onset of ST↓ - Time to onset of ST segment depression in seconds,
Time to offset of ST↓ - Time to offset of ST segment depression in seconds
7.Follow-up events in the study population :
The  follow-up  events  in  the  study  population  are  depicted  in  Table  7  and  Graph  1.The 
occurrence of angina was significantly greater in the slow flow group at 30 days follow up versus 
normal  flow (46  % versus  30  %).The  incidence  of  hospitalization  for  intractable  angina  was  not 
significantly different between the two groups ( 5 % versus 4 %).
 
                                                                  Table 7                                                 
FOLLOW-UP
EVENT VARIABLE
GROUP-I
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
ANGINA           26(46%)         15(30%)         < 0.05
HOSPITALIZATION              3(5%)           2(4%)            0.35
Anginal episode 
Hospitalization for Angina  
All in the follow-up period
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                                                      Graph 1
Follow-up data in Group I – Slow flow and Group II – Normal flow expressed as % of patients 
presented with Angina Pectoris / Hospitalization.
ANG. – Angina,HOSP. - Hospitalization
8.Incidence of NOCAD and CSFP :
The  incidence  of  CAD  patients  with  NOCAD  was  5  %  and  that  of  CSFP  3%  at  our 
cardiovascular catheterization laboratory among patients undergoing CAG.
9. Angiographic Characteristics of slow flow group :
Relevant findings on angiography for the slow flow group are depicted in Tables 8-10. and 
Graphs 2-4.The mean CTFC was 51.3 ± 5.4 for LAD,36.9 ± 4.6 for LCX and 32.5 ± 3.3 for RCA.Mean 
CTFC for all the three vessels was 41.6 ± 5.7.The difference between the measures was statistically 
highly significant for the slow flow versus normal flow groups.21 %  of the patients  had 3 vessel 
involvement  in  CSFP while  37  % and  42  % had  involvement  of  2  and  1  vessel  respectively  in 
CSFP.LAD was the commonest involved vessel seen in 67 % of slow flow patients followed by RCA 
at 59 % and finally LCX at 52 %.        
                                                               Table 8
ANGIOGRAPHIC
VARIABLE
GROUP-I
SLOW FLOW
GROUP-II
NORMAL FLOW
P
VALUE
LAD / 1.7        51.3 ± 5.4       22.6 ± 1.7      < 0.001
LCX        36.9 ± 4.6       22.9 ± 2.3      < 0.001
RCA        32.5 ± 3.3       21.5 ± 2.8      < 0.001
Mctfc        40.3 ± 5.7       22.3 ± 3.6      < 0.001
LAD / 1.7 – CTFC of LAD, mCTFC – mean CTFC of LAD/1.7,LCX and RCA                          
All in number of cine-frames                        
                     
                                                                 Table 9
ANGIOGRAPHIC
VARIABLE
GROUP-I
SLOW FLOW
1 VESSEL       24 (42%)
2 VESSEL       21 (37%)
3 VESSEL       12 (21%)
                               
                               At least 1,2 or 3 vessel involvement
                                                                Table 10
ANGIOGRAPHIC
VARIABLE
GROUP-I
SLOW FLOW
LAD       38 (67%)
RCA       34 (59%)
LCX       30 (52%)
                               
                               Target vessel with CSFP   
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                                                                Graph  2
CTFC in number of frames expressed as Arithmetic mean ± 1 S.D. in each of      the 3 vessels 
LAD,LCX and RCA,mean CTFC is displayed at the last.
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                                                                 Graph 3
     Number of vessels involved in slow flow – At least 1,2 or 3 vessel involvement.     
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                                                          Graph 4
             Percentage of slow flow cases with LAD,LCX and RCA involvement.
                                     ILLUSTRATIVE  CASE PROFILES
SLOW FLOW PROFILES
1) Mr.Nawab Jan / 55 / M / CAG No : 819 / 06 / MRD No : 862040 
    Smoker,Hypertensive,f/h of CAD +,
    Recurrent angina on follow up,
    On Nitrates,Beta  blockers and Calcium Channel Blockers.
                                                          
TMT profile
              
                  
                                              Total Work load 10.1 METS
                                              Total Exercise duration 411 s 
                                              Time to onset of ST ↓ 265 s   
                                              Time to offset of ST ↓ 532 s 
                                                           
                                                                                                                                       
        
                                                              CAG profile
                                      
                                               CTFC OF LAD - FRAME 1
                                      
                                             CTFC OF LAD - FRAME 56 
                                                                                                                                       
2)Mr.Shahul Hameed / 53 / M / MRD No : 853913
   Hypertensive,f/h of CAD+
   Recurrent Angina on follow up,
   On Nitrates,Beta Blockers and Calcium Channel Blockers
                                                          TMT profile
               
                                                                                                                                       
                  
                                                Total Work load 9.4 METS
                                                Total Exercise duration 420 s 
                                                Time to onset of ST ↓ 258 s   
                                                Time to offset of ST ↓ 497 s 
                                                         
                                                           CAG profile
                                
                                           CTFC OF LCX - FRAME 1
    
                                 
                                        CTFC OF LCX -  FRAME  41
3)Mrs.Pathuma / 53 / F / MRD No : 844027   
   Smoker,Hypertensive,Dyslipidaemic,f/h of CAD +,
   Recurrent angina on follow up,
   On Nitrates,Beta  blockers and Calcium Channel Blockers.
                          
                                                                  TMT profile
                    
                                                                                                                                       
                    
                                                    Total Work load 9.2 METS
                                                    Total Exercise duration 419 s 
                                                    Time to onset of ST ↓ 354 s   
                                                    Time to offset of ST ↓ 530 s 
                                                        
                    
                                                             CAG profile
                     
                                 
                                             CTFC OF RCA - FRAME 1
                                   
                                           CTFC OF RCA - FRAME  31                                                               
                                                                                                                                       
NORMAL FLOW PROFILE
Mrs.Rajammal / 64 / F / MRD No : 857273
Diabetic,Dyslipidaemic
No recurrent angina on follow up,
On Nitrates.
                                                             TMT profile
                
                    
                                              Total Work load 12.8 METS
                                              Total Exercise duration 485 s 
                                              Time to onset of ST ↓ 354 s   
                                              Time to offset of ST ↓ 411 s 
                                                       
                                                      CAG profile
                          
                                  CTFC OF RCA -  FRAME 18
                          
                                     CTFC OF LAD -  FRAME 20
                            
                                    CTFC OF LCX -  FRAME 20
DISCUSSION
Comparison with other Studies
There  is  a  growing  body  of  evidence  that  CSFP  is  a  unique  clinical  subset  in  NOCAD 
characterized  by  delayed  opacification  of  epicardial  coronary  arteries  during  selective  coronary 
angiography in the absence of obstructive epicardial coronary disease.However consensus is lacking in 
the characterization of the same.
A.Mehta,R Passey,J P N Sawhney et al(58)reported that  slow flow is more common in female 
patients. Females were younger than males by a decade in their study. Hypertension, diabetes mellitus, 
and  dyslipidemia  are  more  commonly  associated  in  both  females  and  males.  Smoking  is  the 
commonest association in male patients. All the females were pre-menopausal.
On the other hand Falgun Panchal,Narendra S Tanwar,Sanjay C Shah et al(57) report that patients 
with slow flow are more likely to be men,diabetics with typical angina and positive stress test, and 
more likely to be on antianginals as compared to patients with normal coronaries.
Goel P K,Gupta S K,Agarwal A et al(56)concluded differently that CSFP patients constitute a 
definite subset within the wide spectrum of syndrome X and that the phenomenon of SCF could be 
used as a marker for myocardial ischemia.My contention is that Cardiac syndrome X and CSFP are 
mutually exclusive subsets of NOCAD.
Thus it is evident from the divergent conclusions of the above studies vis a vis my conclusions 
that  CSFP  has  not  been  unambiguously  characterized.There  exists  a  scope  for  further  accurate 
characterization of clinical profile and the natural history in CSFP at least in the Indian sub continent 
with its impending pandemic of CAD.  
Several other studies have focused on different niche aspects of CSFP,but paucity of literature 
does not permit immediate comparisons nor definite conclusions regarding the study questions.
Ertin Yetkin,Hasan Turhan,A.Riza Erbay et al(62)state that  patients with MI and NOCAD have 
higher TIMI frame counts for all coronary arteries when compared to patients without MI and NOCAD. 
Absence of difference between smokers and non-smoker in the myocardial infarction group in respect 
to TIMI frame count, has suggested that smoking does not lead to further increase of TIMI frame 
counts. On the other hand, in patients without MI and with NOCAD, smokers have higher TIMI frame 
counts  than non-smokers have. Increased TIMI frame count of patients  with MI and NOCAD has 
suggested that, whatever the real mechanism underlying this phenomenon, decreased coronary flow 
rate may be a common step in the pathogenesis of myocardial infarction with normal coronary arteries. 
Additionally, when considering the high percentage of smoking status without any increasing effect on 
TIMI frame count in myocardial infarction group, cigarette smoking can be considered as a triggering 
factor to initiate myocardial infarction.My study albeit different was similar in concluding that smokers 
are more likely to have CSFP in NOCAD patients.
As per the conclusions of Emrah Binak,Huseyin Gunduz,Muslum Sahin et al(60)There was no 
difference between slow
 flow  and  normal  flow  with  respect  to  age,  fasting  plasma  glucose,  triglyceride,  total 
cholesterol, high density lipoprotein, low density lipoprotein, hemoglobin A1c, systolic–diastolic blood 
pressure levels, history of smoking and alcohol consumption.Plasma glucose at 2 h of oral glucose 
tolerance test  was  significantly higher  in slow coronary flow patients  compared to  normal  flow.In 
addition, the number of patients who met the criteria of impaired glucose tolerance was significantly 
higher in slow flow group.Their results suggest that impaired glucose tolerance may be an independent 
etiological factor for slow flow phenomenon.In my study diabetics and fasting blood glucose values 
were not significantly different between the slow flow and normal  flow groups.
Dogan Erdogan,Mustafa Caliskan,Hakkan Gullu et  al(59) state that demographic features, 
coronary  risk  factors  and  echocardiographic  measurements  except  diastolic  function 
parameters and biochemical measurements are similar between the slow flow and normal 
flow groups.Coronary Flow Reserve values are significantly lower in subjects with CSFP than 
in the control group. In addition, TIMI frame count independently correlated with Coronary 
Flow  Reserve.They  suggested  that  Coronary  Flow  Reserve,which  reflects  coronary 
microvascular function, is impaired in patients with  CSFP, and CTFC well correlates with 
Coronary  Flow  Reserve.I  would  prefer  to  treat  microvascular  angina  and  CSFP  as  two 
different exclusive subsets of NOCAD. 
Sezgin AT,Topal E,Barutcu I  et  al(64)studied the echocardiographic features in patients  with 
CSFP. There were no significant differences with respect to systolic parameters between the slow flow 
and normal flow groups; in spite of these, group I showed impaired left ventricular diastolic patterns 
compared to group II. Group I patients had higher peak late diastolic filling velocities due to enhanced 
atrial systole (A), lower peak (E/A) diastolic filling velocity ratios, and longer isovolumetric relaxation 
times compared with group II, and these were statistically significantIn conclusion; the authors detected 
diastolic  filling  abnormalities  and  showed  diastolic  dysfunction  in  patients  with 
SCF.Echocardiographic evaluation was normal in both slow flow and normal flow groups in my study.
One  contemporary  study  focused  on  the  arrythmogenic  potential  of  CSFP.Sait 
M.Dogan,Nesligul  Yildirim,Metin  Gursurer  et  al(63)state  that  there  was  no  statistically  significant 
difference  between  the  slow flow and  normal  flow groups  with  respect  to  age,sex,  hypertension, 
diabetes mellitus, hyperlipidemia, and cigarette smoking.P-wave dispersion and P-wave duration both 
were found to be greater in patients with slow flow than in normal flow marking its arrythmogenic 
potential for atrial fibrillation.All my study subjects however had a normal resting ECG.
Ergun  Topal,Ramazan  Ozdemir,Irfan  Barutcu  et  al(61)  studied  the  effects  of  short-term 
trimetazidine therapy on CSFP.They concluded that it improved Heart Rate Variability  parameters and 
endothelial products such as Endothelin-1 and Nitric Oxide as well as anginal symptom in patients with 
SCFP. Trimetazidine was not prescribed to any of my study patients
The 3 % incidence of CSFP and 5% of NOCAD at our cardiovascular catheterization laboratory 
observed in my study was quite different from the varying reports of 1 % and 7 %  reported by various 
investigators (5,6).
Generalization of Observation / Explanation for variation
A perusal of the above discussed original papers shows consistency of observation in certain 
spheres but discordance in others.I would like to attribute it to varying study populations and differing 
case  inclusion/exclusion  criteria.Furthermore  the  study  population  noted  in  the  studies  were  not 
homogenous. The reference cut off for definition of slow flow versus normal flow also varied between 
studies and this could be an important contributor to the inconsistency in observations.
Study Highlights
This study is unique in that it addresses Coronary Slow Flow Phenomenon in a homogenous 
subset  of  stable  CAD,that  is  NOCAD patients  with  no  prior  or  current  history of  acute  coronary 
syndrome.Objective  parameters  for  diagnosing  CAD  were  employed  in  all  the  study  subjects 
eliminating the element of subjective bias in diagnosis.Stringent inclusion and exclusion criteria were 
employed to ensure that the conclusion of the study is not due to chance.Hitherto numerical values for 
slow flow in the individual coronary arteries with reference to the international reference range has not 
been published from the Indian sub continent,to the best of my knowledge.In addition currently there is 
no data available on comparison between various measures of ischaemia and functional capacity on 
TMT in NOCAD subsets from the Indian subcontinent.Emphasising on the South Indian population as 
a distinct ethnic group at a unique and great risk of CAD,this study humbly strives to throw some light 
on  the “Coronary Slow Flow Syndrome”.                                                                            
Study Limitations
Several limitations of this study have been kept in mind.
The follow-up of patients  was for a period of 30 days  only.More long term follow-up and 
possibly repeat coronary evaluation may be necessary to study the natural history of “Coronary Slow 
Flow Syndrome”.
The angiographic definition  of normal coronary arteries relies on axial contrast angiograms of 
the vessel lumen which underestimate the presence of atherosclerotic plaque.A contributing factor to 
insensitivity of angiography for detection of plaques is that atherosclerosis is associated with medial 
atrophy and vessel wall dilatation resulting in diffusely diseased coronary arteries appearing to have 
angiographically normal lumen.Given the inherent limitation of angiography, it is not surprising that 
there  is  limited  information  about  the  true  prevalence  of  plaques  in  patients  with  coronary artery 
disease and normal coronary arteries.IVUS overcomes the limitation of angiography with tomographic 
images which provide accurate characterization of vessel  lumen and wall geometry,  as well as the 
presence and distribution of atherosclerotic  plaques.These advantages mean that  IVUS is  the most 
sensitive technique for detecting the presence of coronary atherosclerosis in patients  with coronary 
artery disease and angiographically normal coronary arteries.However,I did not have the opportunity to 
perform IVUS.
Another  potential  limitation  of  the  study is  precisely unknown etiology of  angina  pectoris. 
Although I have excluded patients with valvular heart disease, atrial fibrillation, infective endocarditis, 
vasculitis  and  hematological  disease  in  order  to  eliminate  potential  embolic  source,  the  exact 
mechanism of  chest  pain with normal coronary angiogram  and slow flow is  still  unclear.  Acute 
myocarditis, particularly of infectious origin (Coxsackie virus), may simulate CAD  in patients with 
normal coronary arteries. Atrial myxoma, and mitral valve prolapse has been implicated as a potential 
cause of angina pectoris with normal coronary arteries, which may be true in an exceedingly small 
number of patients.
Prior studies have shown that the volume, rate and pressure of the contrast injection as well as 
the coronary catheter size have little effect on the frame count.Because the timing, volume and pressure 
of the contrast  injection were not controlled in the study, this probably would introduce a random 
amount  of  error  into  my measurement  of  frame count.  Although there  are  significant  associations 
between CTFC and certain clinical and hemodynamic variables such as BP,PR, gender,BSA, and age, 
the absolute  change in  frame count  is  fairly small.  And these differences  may be important  when 
establishing the normal CTFC value.
CONCLUSION
Conclusions from this study are :
1.Non Obstructive  Coronary  Artery Disease  has  an  incidence  of  5  % among  patients  undergoing 
Coronary Angiography.
2.Coronary Slow Flow Phenomenon has an incidence of 3 % among patients undergoing Coronary 
Angiography.
3.Non Obstructive Coronary Artery Disease with Coronary Slow Flow Phenomenon is more prevalent 
among males as compared to females,they are more likely to be smokers and hypertensive with a 
family history of Coronary Artery Disease.
4.Non Obstructive Coronary Artery Disease patients with Coronary Slow Flow Phenomenon achieve 
comparatively a lesser work load,have a shorter total exercise duration with an earlier onset and a later 
offset of ST depression on Tread Mill Test.  
5.Coronary Slow Phenomenon is commonest in a single coronary artery with an incidence of 47 % and 
the Left Anterior Descending Coronary Artery is the most commonly affected vessel at 68 % incidence 
in Non Obstructive Coronary Artery Disease.
6.Coronary  Slow Flow Phenomenon is characterized by a CTFC of 51.3  ± 5.4           frames for 
LAD,36.9  ±  4.6 frames for LCX , 32.5  ±  3.3 frames for RCA and a mean CTFC for all the three 
coronary vessels  of  41.6  ± 5.7 frames in an urban South Asian Population with Non Obstructive 
Coronary Artery Disease,The CTFC values are similar to the figures  published internationally in the 
literature incorporating varying populations of  different ethnic origins.Hence Corrected TIMI Frame 
Count can be a universally applicable tool in segregating Non Obstructive Disease patients in to slow 
flow and normal flow sub-sets. 
7.Non  Obstructive  Coronary  Artery  and  Coronary  Slow  Flow  Phenomenon  is  correlated  with  an 
adverse clinical outcome – these patients have recurrent  anginal episodes on out-patient follow up and 
are  more likely to require  combination therapy with at  least  three different  classes  of  anti-anginal 
medications for better anginal relief and improved quality of life.
On  the  basis  of  the  above  conclusion  the  study  hypothesis  that  “Coronary  Slow  Flow 
Phenomenon” in Non Obstructive Coronary Artery Disease indeed represents a novel disease entity 
aptly to be termed the“Coronary Slow Flow Syndrome” is proved true.   
Scope for further exploration in “Coronary Slow Flow Syndrome”:
 “Coronary Slow Flow Syndrome” is still  inadequately characterized and its natural  history 
remains unclear.A larger study with a greater number of patients and a longer duration of follow up 
should throw more light on the same.
Further  more  a  lot  of  work  needs  to  be  done  on  the  Echocardiographic  and  Biochemical 
characteristics of “Coronary Slow Flow Syndrome.”This could eventually help in better understanding 
of the aetiopathogenesis,defining better  anti-anginal  regimens  and ultimately help improve patient 
care.      
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GLOSSARY OF ABBREVIATIONS & ACRONYMS
mm Millimeter
MPG MYOCARDIAL PERFUSION GRADE
NOCAD NON OBSTRUCTIVE CORONARY ARTERY DISEASE
OM OBTUSE MARGINAL BRANCH
PLV POSTERO-LATERAL VENTRICULAR BRANCH
PR PULSE RATE
RCA RIGHT CORONARY ARTERY
S Second
TIMI THROMBOLYSIS IN MYOCARDIAL INFARCTION
TMPG TISSUE MYOCARDIAL PERFUSION GRADE
TPG TIMI PERFUSION GRADE
APS ANGIOGRAPHY PERFUSION SCORE
BP BLOOD PRESSURE
BSA B DY SURFACE AREA
CAD CORONARY ARTERY DISEASE
CAG C RONARY ANGIOGRAM
CCS CANADIAN CARDIOVASCULAR SOCIETY
CFR CORONARY FLOW RESERVE
CSFP CORONARY SLOW PHENOMENON
(C)TFC (CORRECTED) TIMI FRAME COUNT
ECG ELECTROCARDIOGRAM
ECHO ECHOCARDIOGRAM
FFR FRACTIONAL FLOW RESERVE
fps frames per second
IVUS INTRAVASCULAR ULTRASOUND
LAD LEFT ANTERIOR DESCENDING
LCX LEFT CIRCUMFLEX
METS METABOLIC EQUIVALENTS
m Minute
SPECIMEN PROFORMA
“CORRECTED TIMI FRAME COUNT IN CORONARY SLOW 
FLOW PHENOMENON”
A SHORT-TERM FOLLOW-UP STUDY
DEMOGRAPHIC DATA 
NO :
NAME : 
AGE :                                                                        SEX : 
MARITAL STATUS :
EDUCATIONAL LEVEL :
OCCUPATION/INCOME :      
CD NO :                                                                      IP NO :
ETHNICITY :
HISTORY
CHEST PAIN                                         PALPITATION
DYSPNOEA
SYNCOPE 
RISK FACTOR ASSESSMENT
HYPERTENSION                                                    OBESITY
DYSLIPIDAEMIA                                                   FAMILY HISTORY
FAMILY HISTORY    
DIABETES
SMOKING :             PACK YEARS        
PHYSICAL EXAMINATION 
GENERAL EXAMINATION 
BODY MASS INDEX                        kg/m2
OTHERS
CARDIOVASCULAR EXAMINATION 
VENOUS & LYMPHATIC SYSTEM 
JVP                                                     cm   H2O        OTHERS                                       
WAVEFORM
ARTERIAL SYSTEM 
PERIPHERAL PULSATION                                   OTHERS
BLOOD PRESSURE                        mm Hg
HEART
INSPECTION / PALPATION / PERCUSSION / AUSCULTATION
OTHER SYSTEMS 
INVESTIGATIONS 
BLOOD BIOCHEMISTRY
LIPID PROFILE
COMPLETE BLOOD COUNT
RESTING ELECTROCARDIOGRAM (ECG)
ECHOCARDIOGRAM (ECHO)
COMPLETE CLINICAL DIAGNOSIS
MEDICATIONS
NITRATES                                                                                YES / NO
BETA-BLOCKERS                                                                   YES / NO
CALCIUM CHANNEL BLOCKERS                                       YES / NO
TREADMILL TEST (TMT)
TMT No :                                    Date of procedure :         Protocol :
Total Workload :                                                                  METS 
Total Exercise duration :                                                      seconds      
Time to onset of ST segment depression :                           seconds
Maximum ST segment depression :                                     mm
Time to offset of  ST depression in to recovery :                seconds      
CORONARY ANGIOGRAPHY(CAG)
CAG No:                                                    Date of procedure :
Technique :                                                      Medications : 
Catheters used :                                               Approach :   
Contrast medium :                                                                       
RESULT
Coronary flow status :            LAD/1.7                FPS            Slow / Normal flow
TARGET
VESSEL
CORRECTED  TIMI  FRAME
COUNT (FPS) / 12.5 × 30
 LAD / 1.7                   
   LCX 
   RCA 
                      LCX                       FPS            Slow / Normal flow
                                            RCA                      FPS             Slow / Normal flow
Mean CTFC = { ( LAD/1.7 + LCX + RCA ) / 3 }  FPS
REFERENCE RANGE(51)                           SLOW FLOW(51)
LAD/1.7      21.1 ± 1.5 frames                > 24.3 frames
LCX            22.2 ± 4.1 frames                > 30.4 frames 
RCA            20.4 ± 3.0 frames                 > 26.4 frames 
FOLLOW-UP
Anginal episode :                                                        Yes / No
Hospitalization for angina :                                         Yes / No
 
      DATA CHARTS           1.CLINICAL,HEMODYNAMIC AND BIOCHEMICAL DATA – 
STUDY GROUP (I)
SERIAL 
NO : NAME
SE
X AGE SHT DM DYSLIP. F.HIST. SMOK.
BMIk
g/m2
BP
PR
A.A TC mg%
LDL 
mg%
HDL 
mg %
1 BABU M 62 Y Y Y Y Y 24.5 128/80
65
3 169 111 32
2 PALANI M 57 Y Y Y Y Y 32.7 126/84
68
3 216 144 58
3 SESHADRI M 59 Y Y Y Y Y 26.9 134/90
72
3 172 126 46
4 PARASU M 48 Y Y Y Y Y 24.8 130/86
70
3 187 135 48
5 BASHA M 52 Y Y Y Y Y 26.5 128/88
71
3 211 142 57
6 LEELA F 55 Y Y Y Y N 28.7 124/86
72
3 210 143 53
7 ELUMALAI M 59 Y Y Y Y Y 28.8 128/84
74
3 174 138 54
8 RAJI F 62 Y Y Y N N 31.6 126/82
70
3 216 140 51
9 ROSY F 64 Y Y Y N N 32.4 138/72
68
3 210 142 48
10 PREMALATHA F 67 Y Y Y N N 31.6 128/76
70
3 201 145 32
11 THANGARAJ M 66 N Y N N Y 31.5 126/78
70
3 209 142 36
12 CHELLAM M 39 Y Y N N Y 32.6 124/82
74
3 210 116 37
13 VADIVAMMAL F 42 Y Y N N N 31.7 126/84
70
3 212 121 50
14 SARAVANAN M 46 Y Y Y N Y 32.4 124/78
66
2 214 124 54
15 PERUMAL M 62 Y Y Y N Y 31.7 128/80
68
2 215 126 56
16 NAGAMALAR F 59 N Y Y Y N 31.5 126/84
71
2 216 137 38
17 SHAHUL M 53 Y N Y Y N 24.6 120/84
74
3 210 138 40
18 PATHUMA F 53 Y N Y Y N 26.8 124/84
75
3 208 142 42
19 NAWAB M 55 Y N N Y Y 28.8 140/90
74
3 209 128 44
20 YAKOUB M 35 Y N N N Y 27.9 140/82
74
3 178 134 47
21 MANOHARAN M 47 Y Y N N Y 28.8 136/86
78
3 198 142 52
22 SRINIVASAN M 45 Y Y Y Y Y 31.6 134/92
74
3 178 141 55
23 SIVARAMAN M 48 N Y Y Y Y 28.8 140/80
68
3 185 138 56
24 GOVINDASAMY M 52 Y Y Y Y Y 26.8 136/84
68
3 188 139 33
25 KISHORE M 62 Y Y Y Y Y 25.8 130/80
66
3 190 141 35
26 ABDUL AZIZ M 55 Y Y Y Y Y 27.8 128/84
66
3 192 128 36
27 SHABAN M 61 Y Y Y Y Y 30.6 132/86
64
3 198 131 42
28 CHITTI BABU M 57 Y Y Y Y Y 31.7 136/84
74
3 200 135 44
29 SELVAM M 58 N Y Y Y Y 32.4 138/90
70
3 210 138 46
30 SELVA KUMAR M 56 Y Y Y Y Y 30.8 134/84
70
3 212 139 55
31 MURUGAN M 55 Y Y Y Y Y 26.8 130/82
72
3 214 141 56
32 ROBERT M 48 Y Y Y Y Y 28.9 130/86
74
3 213 125 35
33 MASIMA F 61 Y Y Y Y N 29.9 128/82
75
3 216 138 38
34 SAVITHA F 49 Y Y Y Y N 30.5 130/84
72
3 178 118 39
35 CHANDRA F 53 Y Y Y Y N 31.8 128/82 2 187 114 41
76
36 MANOHARAN M 54 Y Y Y Y Y 31.7 130/84
74
2 198 129 44
37 MOHAN M 63 Y Y Y Y Y 28.6 130/90
74
3 199 135 46
38 GOVND REDDY M 55 Y Y Y Y Y 31.6 130/84
74
3 174 133 54
39 CHINATHAMBY M 53 Y Y Y Y Y 28.8 128/86
72
3 175 134 37
40 SAROJA F 54 Y Y Y Y N 30.6 128/90
74
3 177 137 38
41 JAYA F 49 Y Y Y Y Y 29.6 130/84
74
3 178 135 47
42 LAKSHMI F 37 Y Y Y Y N 25.6 130/84
72
3 179 141 54
43 DEVAKI F 38 Y N N N N 26.8 126/86
74
2 186 141 55
44 MAHENDRAN M 42 Y N N N Y 29.8 128/90
74
2 188 138 35
45 VEERAMAL F 48 Y N N N N 28.6 126/86
76
1 189 121 36
46 KANAGARAJ M 46 Y N N N Y 29.5 128//9
2
68
1 191 126 37
47 RANGASAMY M 49 Y N N N Y 30.8 130/92
72
1 174 129 39
48 ARUMUGAM M 52 N N N N Y 31.6 130/92
74
1 175 135 56
49 SANKAR M 59 N N N N Y 30.5 130/90
74
1 176 138 57
50 KANI M 58 N N N N Y 31.6 128/90
72
1 177 132 38
51 MOHIDEEN M 56 N N N N Y 30.2 126/92
74
1 178 141 43
52 KRISHNAN M 48 N N N N Y 31.3 130/78
74
1 198 118 44
53 VASANTH M 39 N N N N Y 30.7 136/72
68
1 199 124 48
54 RAJ MOHAN M 36 N N N N N 31.5 134/90
70
1 200 129 56
55 ASOKAN M 38 N N N N N 29.5 136/86
68
1 179 138 54
56 GEORGE M 42 N N N Y Y 30.6 134/78
66
1 189 141 55
57 HARI M 49 Y N N Y Y 28.8 136/78
69
1 194 142 53
Legend  :  SHT-Systemic  Arterial  Hypertension,DM-Diabetes  Mellitus,DYSLIP.-
Dyslipidaemia,F.Hist.-Family  History  of  CAD,SMOK.-Active  &  Current  Smoking 
History,Y  -  Present,N  -  Absent,BMI-Body  Mass  Index,PR-Pulse  Rate,BP-  Blood 
Pressure  in  mmHg,A A  –  At  least  1,2  or  3  classes  of  anti-anginals-  Nitrates,Beta 
blockers,Calcium  channel   blockers,TC-  Total  Cholesterol,LDL-  Low  Density 
Cholesterol,HDL-High Density Cholesterol,TGL-Triglycerides,B.GLU.-  Blood Glucose,
(All on fasting venous samples).       
                                                                  
                               CLINICAL,HEMODYNAMIC AND BIOCHEMICAL DATA – CONTROL 
GROUP (II)
SERIAL
NO:
NAME SEX AGE SHT DM DYSLIP. F.HIST. SMOK.
BMI
kg/m2
BP
PR
AA
TC
mg%
LDL
mg%
HDL
mg%
1 RAJAMMAL F 64 N Y Y N N 24.8 120/76
74
1 145 105 29
2 RAVI M 68 Y N Y Y Y 31.6 120/80
78
3 233 142 56
3 RAMALINGAM M 69 Y N Y Y Y 24.9 138/79
86
2 165 109 32
4 MANICK M 42 Y Y Y N Y 26.6 130/84
90
3 230 140 34
5 RAGUNATHAN M 41 Y Y Y Y Y 30.5 126/84
76
2 228 138 36
6 MAHADEVI F 46 Y Y Y N N 31.2 128/82
78
3 167 141 48
7 SEETHALAKSHMI F 52 Y Y Y Y N 30.6 136/76
65
3 176 106 51
8 KUPPAN M 53 Y Y Y N Y 31.4 130/90
78
3 198 112 54
9 RAMAKRISHNAN M 58 Y Y Y Y Y 29.8 122/78
65
3 225 114 55
10 DEVA DAN M 48 Y N Y Y Y 30.6 126/86
78
3 230 115 53
11 SURESH M 47 Y N N Y Y 31.4 136/88
78
3 228 139 32
12 JAYACHANDRAN M 56 N Y Y N Y 30.7 130/74
66
2 167 134 34
13 USHA F 54 N Y Y N N 28.8 120/74
65
3 168 137 38
14 RAMASAMY M 53  N Y  Y  Y  Y 25.2 122/76
68
 3 194 129 47
15 MANOHARAN M 58  N N  Y  Y  Y  26.8 124/78
66
 3    187 132 46
16 VISALAKSHI F 59  Y Y  Y  Y  N 28.8 128/76
78
 2 183 140 44
17 RAJALAKSMI F 65  Y Y  Y  Y  N 30.4 120/776
90
 3 185 122 48
18 VEERARAJAN M 66  Y Y  Y  Y  Y 26.6 124/86  2 210 127 52
76
19 RAGAVAN M 62  Y N  N  Y  Y 30.4 122/86
80
 3  213 109 54
20 MOHAN M 48  Y Y  Y  Y  Y 30.4 136/76
76
 2 224 111 38
21 SUBRAMANI M 59  Y Y  Y  N  Y 29.6 124/82
78
 3 226 132 45
22 SATHYAMURTHY M 68  Y Y  Y  Y  Y 25.8 134/88
66
 2 228 127 51
23 SYED M 69  Y N  N  N  Y 28.8 136/76
78
 3 231 140 47
24 MOHD.  IQBAL M 64  Y Y  Y  Y  Y 29.6 132/74
78
 2    159 119 36
25 MURUGAN M 58  Y Y  N  Y  Y 27.8 136/76
74
 3 164 134 38
26 DHANDAYUDHAM M 55  Y Y  Y  Y  Y 25.6 132/90
79
 2 224 118 44
27 GOWRI F 54  Y N  N  Y  N 27.8 136/90
78
 2 228 132 46
28 RAJESH M 53  Y Y  Y  Y  Y 30.2 134/78
79
 2    231 124 48
29 VEERASAMY M 54  Y Y  Y  N  Y 29.6 122/88
68
 2 178 127 53
30 SAROJA DEVI F 56 Y Y Y N N 25.8 126/76
68
2 188 132 47
31 GAYATHRI F 58 Y N N Y N 26.8 130/88
78
2 205 108 46
32 CHITRA F 48 N Y Y Y N 30.4 132/74
76
1 231 106 35
33 BACKYAM F 47 N Y N N N 28.8 124/76
66
1 167 141 38
34 DEIVANI F 52 N N Y N N 30.4 128/78
68
1 178 135 47
35 RANI F 53 Y Y N N N 28.2 132/90
78
1 223 138 52
36 GOWRI F 61 Y Y Y N N 28.6 134/86
78
1 209 140 53
37 KALYANI F 60 N Y N N N 24.8 120/90
78
1 212 129 34
38 SARASWATHY F 62 N N Y N N 26.4 122/88
86
1 225 131 43
39 MARIAMMAL F 58 N Y Y N N 26.2 126/88
79
1 230 118 51
40 KANAMMA F 59 N Y N N N 28.9 120/80
75
1 148 121 54
41 CHANDRAKALA F 63 N N N N N 27.6 124/84
78
1 159 126 29
42 PAVAI F 66 N Y N N N 28.4 128/86 1 168 129 33
78
43 ANJALAKSHI F 61 N Y N N N 26.4 132/88
76
1 182 138 37
44 THANGAMMAL F 64 N Y N N N 27.2 128/80
78
1 189 141 41
45 LALITHA F 55 N N N N N 25.6 130/78
76
1 176 138 45
46 KOKILA F 58 N Y N N N 26.8 122/90
68
1 184 135 48
47 MARIAMML F 59 N N N N N 27.4 124/86
76
1 206 136 42
48 CHANDRA F 54 N N N N N 26.8 126/88
78
1 209 140 43
49 JAYA F 56 N N N N N 29.6 124/78
78
1 231 119 47
50 MARIAMMA F 54 N Y Y N N 31.4 136/78
88
1 224 123 52
 Legend:  SHT-Systemic  Arterial  Hypertension,DM-Diabetes  Mellitus,DYSLIP.-
Dyslipidaemia,F.Hist.-FamilyHistoryof CAD,SMOK.- Active & Current Smoking History, 
Y  -  Present,  N  -  Absent,BMI-Body Mass Index,PR-Pulse Rate,BP Blood Pressure in 
mmHg,A A -  At least 1,2 or 3 classes of Anti-anginals - Nitrates,Beta blockers,Calcium 
channel blockers,TC-Total Cholesterol,LDL-Low Density Cholesterol,HDL-High Density 
Cholesterol,TGL-Triglycerides,B.GLU-Blood Glucose,(All on fasting venous samples).
2. TMT DATA – STUDY GROUP (I)
SER. NO: TMTNO: NAME/SEX/AGE METS EX.DUR  s MAX. ST ↓ mm ONSET OF ST ↓    s
1 986 BABU/M/62 9.2 272 1.0 265
2 998 PALANI/M/57 10.4 420 1.5 393
3 943 SESHADRI/M/59 9.8 296 1.2 272
4 864 PARASU/M/48 10.1 414 1.4 282
5 798 BASHA/M/52 10.4 299 1.0 365
6 984 LEELA/F/55 9.5 386 1.8 386
7 785 ELUMALAI/M/59 9.8 376 1.8 277
8 675 RAJI/F/62 10.3 398 1.6 268
9 993 ROSY/F/64 10.2 403 1.5 277
10 567 PREMALATHA/F/67 10.1 419 1.4 272
11 669 THANGARAJ/M/66 9.4 365 1.8 287
12 845 CHELLAM/M/39 9.3 378 1.0 265
13 876 VADIVAMMAL/F/42 9.8 389 1.8 393
14 887 SARAVANAN/M/46 9.9 398 1.8 287
15 834 PERUMAL/M/62 10.0 412 1.0 298
16 862 NAGAMALAR/F/59 10.1 413 1.8 388
17 876 SHAHUL/M/53 10.3 416 1.6 386
18 784 PATHUMA/F/53 10.4 418 1.5 376
19 765 NAWAB/M/55 10.1 415 1.8 399
20 587 YAKOUB/M/35 10.1 416 1.8 382
21 934 MANOHARAN/M/47 9.2 378 1.8 276
22 987 SRINIVASAN/M/45 9.3 386 1.7 298
23 921 SIVARAMAN/M/48 9.5 384 1.6 391
24 989 GOVINDSAMY/M/52 9.6 382 1.0 265
25 945 KISHORE/M/62 10.4 412 1.7 393
26 976 ABDUL AZIZ/M/55 10.2 416 1.8 265
27 893 SHABAN/M/61 9.8 356 1.9 386
28 761 CHITTI BABU/M/57 9.8 348 1.0 265
29 439 SELVAM/M/58 10.2 411 1.0 393
30 931 SELAKUMAR/M/56 10.1 414 1.5 277
31 549 MURUGAN/M/55 10.2 416 1.2 386
32 785 ROBERT/M/48 10.3 415 1.3 272
33 874 MASIMA/F/61 10.2 405 1.4 392
34 762 SAVITHA/F/49 10.0 408 1.5 288
35 872 CHANDRA/F/53 10.3 411 1.6 278
36 756 MANOHARAN/M/54 9.2 387 1.7 299
37 919 MOHAN/M/63 9.3 395 1.8 272
38 566 GOVIND REDY/M/55 9.6 389 1.7 277
39 654 CHINTHAMBY/M/53 9.8 397 1.8 391
40 887 SAROJA/F/54 9.8 394 1.8 278
41 844 JAYA/F/49 9.9 394 1.0 391
42 643 LAKSHMI/F/37 10.2 412 1.7 279
43 771 DEVAKI/F/38 10.3 414 1.5 285
44 663 MAHENDRAN//42 10.3 411 1.6 393
45 343 VEERAMAL/F/48 10.1 418 1.7 286
46 221 KANAGARAJ/M/46 10.0 419 1.7 390
47 116 RANGASAMY/M/49 9.8 376 1.8 290
48 185 ARUMUGAM/M/52 9.8 387 1.8 299
49 335 SANKAR/M/59 10.1 411 1.9 391
50 339 KANI/M/58 10.4 411 1.0 386
51 556 MOHIDEEN/M/56 10.4 412 1.0 385
52 531 KRISHNAN/M/48 10.1 411 1.0 291
53 513 VASANTH/M/39 10.3 412 1.0 299
54 389 RAJ MOHAN/M/36 10.2 417 1.4 386
55 901 ASOKAN/M/38 10.2 420 1.6 390
56 1450 GEORGE/M/42 10.3 420 1.6 391
57 1323 HARI/M/49 10.4 419 1.8 298
Legend : METS- Total Work load in Metabolic Equivalents,EX.DUR.-Total Exercise 
Duration in seconds,MAX.ST↓-Maximum  ST segment depression,ONSET OF ST↓-Time 
to onset of ST segment depression in seconds,OFFSET OF ST↓- Time to offset of ST 
segment depression in seconds.
  
                                           
                                                       
                                                     
                                                                 TMT DATA – CONTROL GROUP (II)
  SER. NO: TMT  NO: NAME/SEX/AGE MET EX.DUR. s MAX. ST ↓ mm ONSET OF ST ↓ s
1 1329 RAJAMMAL/F/64 11.9 371 1.0 348
2 1236 RAVI/M/68 12.7 515 1.4 494
3 1189 RAMALINGAM/M/69 11.9 386 1.0 484
4 1330 MANICK/M/42 12.4 513 1.2 356
5 1176 RAGUNATHAN/M/41 12.6 398 1.3 358
6 1098 MAHADEVI/F/46 12.1 468 1.4 486
7 1099 SITHALAKSHMI/F/52 12.7 508 1.0 490
8 1176 KUPPAN/M/53 12.5 512 1.0 351
9 1278 RAMKRSHNAN/M/58 11.9 367 1.0 355
10 1345 DEVA DAN/M/48 12.4 378 1.2 368
11 1323 SURESH/M/47 12.4 489 1.4 492
12 1332 JAYCHNDRAN/M/56 12.5 376 1.3 493
13 1285 USHA/F/54 11.9 371 1.2 494
14 1275 RAMASAMY/M/53 12.7 515 1.1 348
15 1260 MANOHARAN/M/58 11.9 386 1.3 490
16 1263 VISALAKSHI/F/59 12.4 514 1.4 491
17 1264 RAJALAKSHMI/F/65 12.6 398 1.0 358
18 1248 VEERARAJAN/M/66 12.6 423 1.0 378
19 1243 RAGAVAN/M/62 12.5 458 1.3 398
20 1290 MOHAN/M/48 11.9 513 1.3 487
21 1276 SUBRAMANI/M/59 12.4 512 1.4 490
22 1338 SATHYMRTHY/M/68 12.5 386 1.3 486
23 1305 SYED/M/69 12.6 389 1.4 367
24 1308 MOHD.IQBAL/M/64 12.6 514 1.3 389
25 1409 MURUGAN/M/58 12.5 512 1.4 490
26 1425 DHANDYUDHM/M/55 11.9 389 1.4 491
27 1472 GOWRI/F/54 12.6 377 1.4 398
28 1077 RAJESH/M/53 12.5 515 1.0 490
29 1177 VEERASAMY/M/54 12.7 378 1.3 494
30 1231 SAROJA DEVI/F/56 12.2 514 1.4 348
31 1188 GAYATHRI/F/58 12.4 386 1.2 367
32 1099 CHITHRA/F/48 12.5 387 1.2 490
33 1232 BACKYAM/F/47 12.7 398 1.1 356
34 1222 DEIVANI/F/52 12.0 514 1.0 371
35 1333 RANI/F/53 11.9 514 1.0 378
36 1201 GOWRI/F/61 12.1 398 1.0 490
37 1094 KALYANI/F/60 12.4 390 1.1 490
38 1087 SARASWATHY/F/62 12.6 377 1.2 486
39 1045 MARIAM/F/58 11.9 398 1.2 356
40 1063 KANAMMA/F/59 12.5 515 1.3 398
41 1154 CHANDRKALA/F/63 12.4 510 1.3 491
42 1266 PAVAI/F/66 12.5 514 1.2 492
43 1163 ANJALAKSHMI/F/61 12.7 399 1.1 476
44 1144 THANGAMMAL/F/64 11.9 436 1.0 348
45 1143 LALITHA/F/55 12.1 515 1.2 494
46 1188 KOKILA/F/58 12.8 398 1.2 348
47 1163 MARIAMMAL/F/59 12.7 377 1.2 487
48 1108 CHANDRA/F/54 12.6 379 1.0 367
49 1009 JAYA/F/56 12.4 510 1.3 389
50 1005 MARIAMMA/F/54 12.3 512 1.3 490
Legend  :  METS-  Total  Work  load  in  Metabolic  Equivalents,EX.DUR.-Total  Exercise 
Duration  in  seconds,MAX.ST↓-Maximum  Tsegment  depression,TIME  TO  ONSET  OF 
ST↓-Time to onset of ST segment depression in seconds,TIME TO OFFSET OF ST↓- 
Time to offset of ST segment depression in seconds.
  
3.CAG DATA – STUDY GROUP (I)
SERIAL NO : CAG NO : NAME/SEX/AGE LAD / 1.7 Frames LCX  frames RCA frames
1 757/05 BABU/M/62 46 25 35
2 761/06 PALANI/M/57 56 38 30
3 770/05 SESHADRI/M/59 57 41 30
4 778/05 PARASU/M/48 49 25 24
5 784/05 BASHA/M/52 24 41 31
6 786/05 LEELA/F/55 51 37 33
7 416/06 ELUMALAI/M/59 54 25 24
8 453/06 RAJI/F/62 56 25 24
9 480/06 ROSY/F/62 56 38 34
10 694/06 PREMALATHA/F/67 53 25 24
11 777/06 THANGARAJ/M/66 24 41 32
12 796/05 CHELLAM/M/39 24 38 33
13 799/05 VADIVAMMAL/F/42 48 41 31
14 810/05 SARAVANAN/M/46 54 39 32
15 816/05 PERUMAL/M/62 56 38 33
16 817/05 NAGAMALAR/F/59 55 25 24
17 711//06 SHAHUL/M/53 24 41 31
18 569/06 PATHUMA/F/53 24 25 31
19 819/06 NAWAB/M/55 56 25 24
20 869/05 YAKOUB/M/35 24 40 32
21 75/05 MANOHARAN/M/47 55 25 24
22 866/05 SRINIVASAN/M/45 24 38 32
23 872/05 SIVARAMAN/M/48 49 25 24
24 881/05 GOVINDASAMY/M/52 51 25 24
25 888/05 KISHORE/M/62 24 35 24
26 895/05 ABDUL AZIZ/M/55 50 25 24
27 906/05 SHABAN/M/61 51 25 24
28 929/05 CHITTI BABAU/M/57 24 36 33
29 995/05 SELVAM/M/58 54 25 24
30 934/05 SELVAKUMAR/M/56 48 25 24
31 949/05 MURUGAN/M/55 52 25 24
32 959/05 ROBERT/M/48 51 24 24
33 975/05 MASIMA/F/61 24 37 31
34 28/05 SAVITHA/F/49 48 24 24
35 36/05 CHANDRA/F/53 24 38 32
36 75/05 MANOHARAN/M/54 24 37 33
37 83/05 MOHAN/M/63 50 24 24
38 980/05 GOVIND REDY/M/55 24 36 31
39 10/05 CHINATHAMBY/M/53 53 24 23
40 119/05 SAROJA/F/54 55 25 24
41 339/05 JAYA/F/49 56 25 24
42 267/05 LAKSHMI/F/37 24 34 33
43 171/05 DEVAKI/F/38 54 24 22
44 110/05 MAHENDRAN/M/42 48 25 31
45 136/05 VEERAMAL/F/48 49 25 31
46 156/05 KANAGARAJ/M/46 52 39 32
47 181/05 RANGASAMY/M/49 24 24 32
48 230/05 ARUMUGAM/M/52 54 38 32
49 232/05 SANKAR/M/59 24 37 31
50 250/05 KANI/M/58 57 39 33
51 264/05 MOHIDEEN/M/56 55 38 24
52 274/05 KRISHNAN/M/48 52 24 33
53 309/05 VASANTH/M/39 23 40 30
54 367/05 RAJ MOHAN/M/36 49 40 34
55 408/05 ASOKAN/M/38 24 35 31
56 886/06 GEORGE/M/42 56 33 34
57 943/06 HARI/M/49 24 38 32
 Legend : LAD / 1.7 – CTFC of LAD, mCTFC – mean CTFC of LAD/1.7,LCX and RCA 
                                                CAG DATA –  CONTROL GROUP (II)
 
SERIAL   NO : CAG NO : NAME/SEX/AGE LAD / 1.7   Frames LCX  frames RCA frames
1 762/06 RAJAMMAL/F/64 20 20 18
2 766/05 RAVI/M/68 24 25 24
3 765/05 RAMALINGAM/M/69 22 21 19
4 771/05 MANICK/M/42 22 22 21
5 772/05 RAGUNATHAN/M/41 23 23 22
6 773/05 MAHADEVI/F/46 20 22 24
7 782/05 SITHALAKSHMI/F/52 23 24 23
8 336/05 KUPPAN/M/58 24 25 23
9 433/05 RAMAKRISHNAN/M/58 21 25 21
10 437/05 DEVADAN/M/48 21 22 20
11 692/05 SURESH/M/47 24 21 19
12 699/05 JAYACHANDRAN/M/56 22 25 18
13 823/05 USHA/F/54 21 20 24
14 826/05 RAMASAMY/M/53 23 21 20
15 829/05 MANOHARAN/M/58 21 22 24
16 841/05 VISALAKSHI/F/59 22 22 23
17 845/05 RAJALAKSHMI/F/65 24 24 22
18 903/05 VEERARAJAN/M/66 21 23 21
19 923/05 RAGAVAN/M/62 22 23 22
20 930/05 MOHAN/M/48 23 24 24
21 966/05 SUBRAMANI/M/59 23 21 23
22 18/05 SATHYAMURTHY/M/68 23 20 23
23 998/05 SYED/M/69 21 25 24
24 1007/05 MOHD.IQBAL/M/64 23 23 19
25 64/05 MURUGAN/M/58 24 25 22
26 72/05 DHANDAYUDHAM/M/55 22 24 21
27 95/05 GOWRI/F/54 22 24 20
28 96/05 RAJESH/M/53 22 22 21
29 115/05 VEERASAMY/M/54 22 21 23
30 150/05 SAROJA DEVI/F/56 22 21 23
31 165/05 GAYATHRI/F/58 21 22 24
32 169/05 CHITHRA/F/48 21 24 21
33 187/05 BACKYAM/F/47 21 23 20
34 432/05 DEIVANI/F/52 23 24 21
35 287/05 RANI/F/53 23 25 22
36 318/05 GOWRI/F/61 23 25 24
37 330/05 KALYANI/F/60 22 22 23
38 386/05 SARASWATHY/F/62 21 24 22
39 442/05 MARIAM/F/58 21 23 24
40 64/05 KANAMMA/F/59 23 23 23
41 984/06 CHANDRAKALA/F/63 22 24 22
42 1047/06 PAVAI/F/66 22 21 21
43 1082/06 ANJALAKSHI/F/61 23 23 22
44 18/06 THANGAMMAL/F/64 24 22 21
45 97/06 LALITHA/F/55 23 23 20
46 265/06 KOKILA/F/58 23 24 19
47 902/06 MARIAMMAL/F/59 22 25 20
48 1011/06 CHANDRA/F/54 24 24 21
49 237/06 JAYA/F/56 22 22 22
50 35/06 MARIAMMA/F/54 24 23 21
  
Legend : LAD / 1.7 – CTFC of LAD, mCTFC – mean CTFC of LAD/1.7,LCX and RCA
4. FOLLOW-UP DATA – STUDY GROUP (I)
SERIAL  NO: NAME/SEX/AGE ANGINAL EPISODE HOSPITALIZATION  FOR ANGINA
1 BABU/M/62 Y Y
2 PALANI/M/57 Y N
3 SESHADRI/M/59 Y N
4 PARASU/M/48 Y N
5 BASHA/M/52 N N
6 LEELA/F/55 Y N
7 ELUMALAI/M/59 N N
8 RAJI/F/62 N N
9 ROSY/F/64 N N
10 PREMALATHA/F/67 N Y
11 THANGARAJ/M/66 N N
12 CHELLAM/M/39 N Y
13 VADIAMMAL/F/42 N N
14 SARAVANAN/M/46 N N
15 PERUMAL/M/62 N N
16 NAGAMALAR/F59 N N
17 SHAHUL/M/53 Y N
18 PATHUMA/F/53 Y N
19 NAWAB/M/55 Y N
20 YAKOUB/M/35 N Y
21 MANOHARAN/M/47 N N
22 SRINIVASAN/M/45 N N
23 SIVARAMAN/M/48 N N
24 GOVINDASAMY/M/52 Y N
25 KISHORE/M/62 Y N
26 ABDUL AZIZ/M/55 Y N
27 SHABAN/M/61 Y N
28 CHITTI BABU/M/57 Y N
29 SELVAM/M/58 N N
30 SELVAKUMAR/M/56 Y N
31 MURUGAN/M/55 Y N
32 ROBERT/M/48 Y N
33 MASIMA/F/61 N N
34 SAVITHA/F/49 Y N
35 CHANDRA/F/53 N N
36 MANOHARAN/M/54 Y N
37 MOHAN/M/63 N N
38 GOVIND REDY/M/55 N N
39 CHINATHAMBY/M/53 Y N
40 SAROJA/F/54 N N
41 JAYA/F/49 N N
42 LAKSHMI/F/37 Y N
43 DEVAKI/F/38 N N
44 MAHENDRAN/M/42 N N
45 VEERAMAL/F/48 Y N
46 KANAGARAJ/M/46 Y N
47 RANGASAMY/M/49 N N
48 ARUMUGAM/M/52 Y N
49 SANKAR/M/59 N N
50 KANI/M/58 Y N
51 MOHIDEEN/M/56 N N
52 KRISHNAN/M/48 Y N
53 VASANTH/M/39 N N
54 RAJ MOHAN/M/36 Y N
55 ASOKAN/M/38 N N
56 GEORGE/M/42 N N
57 HARI/M/49 N N
Y – PRESENT,N – ABSENT
                                                                FOLLOW-UP DATA – CONTROL GROUP (II)
SERIAL    NO : NAME/SEX/AGE ANGINAL EPISODE HOSPITALIZATION  FOR ANGINA
1 RAJAMMAL/F/64 N N
2 RAVI/M/68 Y N
3 RAMALINGAM/M/69 N N
4 MANICK/M/42 N N
5 RAGUNATHAN/M/41 N Y
6 MAHADEVI/F/46 N N
7 SETHALAKSHMI/F/52 N N
8 KUPPAN/M/53 Y N
9 RAMAKRISHNAN/M/58 Y N
10 DEVADAN/M/48 N N
11 SURESH/M/47 N Y
12 JAYACHANDRAN/M/56 Y N
13 USHA/F/54 Y N
14 RAMASAMY/M/53 N N
15 MANOHARAN/M/58 Y N
16 VISALAKSHI/F/59 Y N
17 RAJALAKSHMI/F/65 N N
18 VEERARAJAN/M/66 N N
19 RAGAVAN/M/62 Y N
20 MOHAN/M/48 N N
21 SUBRAMANI/M/59 Y N
22 SATHYAMURTHY/M/68 N N
23 SYED/M/69 Y N
24 MOHD.IQBAL/M/64 N N
25 MURUGAN/M/58 Y N
26 DHANDAYUDHAM/M/55 N N
27 GOWRI/F/54 N N
28 RAJESH/M/53 Y N
29 VEERASAMY/M/54 Y N
30 SAROJADEVI/F/56 N N
31 GAYATHRI/F/58 Y N
32 CHITHRA/F/48 N N
33 BACKYAM/F/47 N N
34 DEIVANI/F/52 N N
35 RANI/F/53 N N
36 GOWRI/F/61 N N
37 KALYANI/F/60 N N
38 SARASWATHY/F/62 Y N
39 MARIAM/F/58 N N
40 KANAMMA/F/59 N N
41 CHANDRAKALA/F/63 N N
42 PAVAI/F/66 N N
43 ANJALAKSHMI/F/61 N N
44 THANGAMMAL/F/64 N N
45 LALITHA/F/55 N N
46 KOKILA/F/58 N N
47 MARIAMMAL/F/59 N N
48 CHANDRA/F/54 N N
49 JAYA/F/56 N N
50 MARIAMMA/F/54                N N
Y – PRESENT,N - ABSENT
